

Appendix 1

Cited References in CHC's Response to the Veterinary Medicines Directorate, June 2010 – www.petvaccine.weebly.com

1. The American Animal Hospital Association (AAHA) Guidelines (<http://www.leerburg.com/special—report.htm>)
2. The American Veterinary Medical Association's (AVMA's) Principles of Vaccination (<http://www.avma.org/issues/vaccination/vaccination.asp>)
3. *Deutsches Aerzteblatt International*, 2010; 107: 279-85
4. Abstract of presentation: Compliance or resistance to current vaccine guidelines?. Presented at The 5th International Veterinary Vaccines and Diagnostics Conference, July 19-24, 2009, Madison, WI USA.
5. Dodds, W.J. 2001. Vaccination Protocols for Dogs Predisposed to Vaccine Reactions. *Journal of the American Animal Hospital*. May/June 2001, Vol. 37, 211-214.)
6. Schultz, R.D. 1998. Current and future canine and feline vaccination programs. *Veterinary Medicine*. March 1998, 233-254.)
7. Schultz, RD. and F.W. Scott. Canine & Feline Immunization. In: Symposium on Practical Immunology. R.D. Schultz, Ed., Vet Clinics of N. Am., Nov. 1978, W.B. Saunders Co.
8. Schultz, R.D. Current and Future Canine and feline vaccination programs. *Vet Med* 3: No. 3,
9. 233-254, 1998.
10. R.D. Schultz / *Veterinary Microbiology* 117 (2006) 75–79
11. Abdelmagid, O.Y., Larson, L., Payne, L., Tubbs, A., Wasmoen, T., Schultz, R., 2004. Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus and distemper virus experimental challenges. *Vet. Ther.* Fall 5 (3), 173–186.
12. Carmichael, L.E., 1999. Canine viral vaccines at a turning point—a personal perspective. In:
13. Schultz, R.D. (Ed.), *Advances in Veterinary Medicine 41: Veterinary Vaccines and*
14. *Diagnostics*. Academic Press, San Diego, pp. 289–307.
15. Elston, T., Rodan, I., Flemming, D., et al., 1988. Report of the American association of feline practitioners and academy of feline medicine advisory panel on feline vaccines. *J. Am. Vet. Med. Assoc.* 212, 227–241.
16. Gill, M., Srinivas, J., Morozov, I., Smith, J., Anderson, C., Glover, S., Champ, D., Chu, H., 2004. Three-year duration of immunity for canine distemper, adenovirus, and parvovirus after vaccination with a multivalent canine vaccine. *Int. J. Appl. Res. Vet. Med.* 2 (4), 227–234.
17. Green, C.E., Schultz, R.D., Ford, R.B., 2001. Canine vaccination. *Vet. Clin. North Am. Sm. An. Pract. Vet.* 31 (3), 473–492.
18. Janeway, C.A., Travers, L.J., Walport, M. (Eds.), 2001. *Immunobiology*. fifth ed. Garland Publishing, New York, pp. 412–420.
19. Larson, L.J., Sawchuck, S., Schultz, R.D., 2002. Duration of vaccinal immunity in a population of clinic dogs. In: *Proceedings 83rd Meeting, Conf. Res. Work Anim. Dis.* St. Louis, Missouri (Abstract 75P).
20. Larson, L.J., Schultz, R.D., 1997. Comparison of selected canine vaccines for their ability to induce protective immunity against CPV-2 infection. *Am. J. Vet. Res.* 58 (4), 360–363.
21. Mouzin, D.E., Lorenzen, M.J., Haworth, J.D., King, V.L., 2004a. Duration of serologic responses to five viral antigens in dogs. *JAVMA* 224 (1), 55–60.
22. Mouzin, D.E., Lorenzen, M.J., Haworth, J.D., King, V.L., 2004b. Duration of serologic response to three viral antigens in cats. *JAVMA* 224 (1), 61–66.

23. Paul, M.A., Appel, M. J., et al., 2003. Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: 2003 Canine Vaccine Guidelines. Recommendations and Supporting Literature.
24. Phillips, T.R., Schultz, R.D., 1992. Canine and feline vaccines. In: Kirk, R.W., Bonagura, J.D. (Eds.), *Current Veterinary Therapy XI*. W.B. Saunders Co., Philadelphia, pp. 202–206.
25. Richards, J., Rodan, I. 2000. 2000 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines.
26. Rimmelzwaan, G.F., Osterhaus, A.D., 1997. The immune response. In: Pastoret, P.P. (Ed.), *Veterinary Vaccinology*. Elsevier Science, Amsterdam, pp. 55–67.
27. Scott, F.W., Geissinger, C.M., 1999. Long-term immunity in cats vaccinated with an inactivated trivalent vaccine. *Am. J. Vet. Res.* 60, 652–658.
28. Schultz, R.D., Appel, M.J., Carmichael, L.E., 1977. Canine vaccines and immunity. In: Kirk, R.W. (Ed.), *Current Veterinary Therapy VI*. WB Saunders Co., Philadelphia, pp. 1271–1275.
29. Schultz, R.D., Scott, F.W., 1978. Canine and feline immunization. *Vet. Clin. North Am.* 8 (4), 755–768.
30. 21. Schultz, R.D., 1980. Theory and practice of immunization. In: Kirk, R.W. (Ed.), *Current Veterinary Therapy VII*. W.B. Saunders Co., Philadelphia, pp. 1248–1251.
31. Schultz, R.D., Appel, M.J., Carmichael, L.E., 1980. Update on canine immunizations. In: Kirk, R.W. (Ed.), *Canine Veterinary Therapy VII*. WB Saunders Co., Philadelphia, pp. 1252–1255.
32. Schultz, R.D., 1998. Current and future canine and feline vaccination programs. *Vet. Med.* 93, 233–254.
33. Schultz, R.D., Conklin, S., 1998. The immune system and vaccines. *Comp. Cont. Educ. Pract. Vet.* 20, 5–18.
34. Schultz, R.D. (Ed.), 1999. *Veterinary Vaccines and Diagnostics Chap. IV Canine and Feline Vaccines*, *Advances in Veterinary Medicine*, vol. 41. Academic Press, San Diego, pp. 289–358.
35. Schultz, R.D., 1999b. Duration of immunity to canine vaccines: what we know and don't know. In: *Proceedings canine infectious diseases: from clinics to molecular pathogenesis*, Cornell University, p. 22.
36. Schultz, R.D., 2000. Considerations in designing effective and safe vaccination programs for dogs. In: Carmichael, L.E. (Ed.), *Recent Advances in Canine Infectious Diseases*. International Veterinary Information Service, <http://www.ivis.org/>.
37. Schultz, R.D., 2004. Results presented at 2004 American College of Veterinary Internal Medicine Convention, Minneapolis MN and American Veterinary Medical Association Convention, Philadelphia PA and available in printed material "Canine Distemper and Vaccination" from Merial Limited, Duluth, GA.
38. R.D. Schultz / *Veterinary Microbiology* 117 (2006) 75–79
39. *Veterinary Therapeutics*, Vol. 5, No. 3, Fall 2004
40. AVMA Council on Biologic and Therapeutic Agents' report on cat and dog vaccines. *JAVMA* 221(10): 1401–1407, 2002.
41. Paul MA, Appel M, Barrett R, et al: Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: Executive summary and 2003 canine vaccine guidelines and recommendations. *JAAHA* 39:119–131, 2003 [published erratum appears in *JAAHA* 39(3):225, 2003].
42. Smith CA: Current concepts: Are we vaccinating too much? *JAVMA* 207(4):421–425, 1995.
43. Bohm M, Thompson H, Weir A, et al: Serum antibody titres to canine parvovirus, adenovirus and distemper virus in dogs in the UK which had not been vaccinated for at least three years. *Vet Rec* 154(15): 457–463, 2004.
44. 35 Tizard I, Ni Y: Use of serologic testing to assess immune status of companion animals. *JAVMA* 213(1): 54–60, 1998.
45. Schultz RD, Conklin S: Serologic (antibody) analysis is an excellent indicator for "immunologic memory" following vaccination for any disease and specific indication of protective immunity for

certain diseases. The immune system and vaccine challenges for the 21st century. *Compend Contin Educ Pract Vet* 20(suppl 8C):5–18, 1998.

46. Appel MJ, Summers BA: Canine distemper: Current status, in Carmichael L (ed): *Recent Advances in Canine Infectious Diseases*. Ithaca, NY, International Veterinary Information Service, Nov. 23, 1999. (Available at www.ivis.org/advances/Infect_Dis_Carmichael/appel/chapter_frm.asp; accessed Aug. 18, 2004.)
47. Truyen U: Canine parvovirus, in Carmichael L (ed): *Recent Advances in Canine Infectious Diseases*. Ithaca, NY, International Veterinary Information Service, Jan. 26, 2000. (Available at www.ivis.org/advances/Infect_Dis_Carmichael/truyen/chapter_frm.asp; accessed Aug. 18, 2004.)
48. Appel MJ: Forty years of canine vaccination. *Adv Vet Med* 41:309–324, 1999.
49. Dodds WJ. Immune-mediated diseases of the blood. *Adv Vet Sci Comp Med* 1983;27:163-196.
50. Dodds WJ. Estimating disease prevalence with health surveys and genetic screening. *Adv Vet Sci Comp Med* 1995;39:29-96.
51. 42. Dodds WJ. More bumps on the vaccine road. *Adv Vet Med* 1999;41:715-732.
52. 43. Hogenesch H, Azcona-Olivera J, Scott-Moncrieff C, Snyder PW, Glickman LT. Vaccine-induced autoimmunity in the dog. *Adv Vet Med* 1999;41:733-744.
53. Schultz R. Current and future canine and feline vaccination programs. *Vet Med* 1998;93:233-254.
54. Tizard I. Risks associated with use of live vaccines. *J Am Vet Med Assoc* 1990;196:1851-1858.
55. Twark L, Dodds WJ. Clinical use of serum parvovirus and distemper virus antibody titres for determining revaccination strategies in healthy dogs. *J Am Vet Med Assoc* 2000;217:1021-1024.
56. Tizard I, Ni Y. Use of serologic testing to assess immune status of companion animals. *J Am Vet Med Assoc* 1998;213:54-60.
57. Phillips TR, Jensen JL, Rubino MJ, Yang WC, Schultz RD. Effects of vaccines on the canine immune system. *Can J Vet Res* 1989;53:154-160.
58. Duval D, Giger U. Vaccine-associated immune-mediated haemolytic anaemia in the dog. *J Vet Intern Med* 1996;10:290-295.
59. Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. *J Autoimmun* 1996;9:699-703.
60. May C, Hammill J, Bennett, D. Chinese shar pei fever syndrome: a preliminary report. *Vet Rec* 1992;131:586-587.
61. Day MJ, Penhale WJ. Immune-mediated disease in the old English sheepdog. *Res Vet Sci* 1992;53:87-92.
62. Dougherty SA, Center SA. Juvenile onset polyarthritis in akitas. *J Am Vet Med Assoc* 1991;198:849-855.
63. Scott-Moncrieff JCR, Snyder PW, Glickman LT, Davis EL, Felsburg PJ. Systemic necrotizing vasculitis in nine young beagles. *J Am Vet Med Assoc* 1992;201:1553-1558.
64. Wilbur LA, Evermann JF, Levings RL, et al. Abortion and death in pregnant bitches associated with a canine vaccine contaminated with blue tongue virus. *J Am Vet Med Assoc* 1994;204:1762-1765.
65. Happ GM. Thyroiditis—a model canine autoimmune disease. *Adv Vet Sci Comp Med* 1995;39:97-139.
66. Rivas AL, Tintle L, Meyers-Wallen V, Scarlett JM, van Tassell CP. Inheritance of renal amyloidosis in Chinese shar-pei dogs. *J Hered* 1993;84:438-442.
67. *Journal of the American Animal Hospital Association* May/June 2001, Vol. 37
68. Bilateral subcutaneous fibrosarcomas in a cat following feline parvo-, herpes- and calicivirus vaccination. De Man MM, Ducatelle RV. *Journal of Feline Medicine & Surgery* 2007 Oct; 9(5): 432-434. www.ncbi.nlm.nih.gov
69. Clinical use of serum parvovirus and distemper virus antibody titres for determining revaccination strategies in healthy dogs. Lisa Twark, DVM; W. Jean Dodds, DVM. *Journal of the American Veterinary Medical Association*. October 1, 2000, Vol. 217, No. 7, Pages 1021-1024. avmajournals.avma.org
70. Do postvaccinal sarcomas occur in Australian cats? G Burton and KV Mason. *Aust Vet J* 1997;

- 75:102-106. www.ncbi.nlm.nih.gov 62. Effects of vaccines on the canine immune system. T R Phillips, J L Jensen, M J Rubino, W C Yang, and R D Schultz. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison 53706. *Can J Vet Res*. 1989 April; 53(2): 154–160. www.pubmedcentral.nih.gov
71. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. Kass PH, Barnes WG Jr, Spangler WL, Chomel BB, Culbertson MR. Department of Epidemiology and Preventive Medicine, School of Veterinary Medicine, University of California, Davis 95616-8735. *J Am Vet Med Assoc*. 1993 Aug 1;203(3):396-405. www.ncbi.nlm.nih.gov
72. Feline Vaccine-associated Fibrosarcoma: Morphologic Distinctions. S. S. Couto, S. M. Griffey, P. C. Duarte and B. R. Madewell. *Vet Pathol* 39:33-41 (2002). www.vetpathology.org
73. 65. Fibrosarcoma with Typical Features of Postinjection Sarcoma at Site of Microchip Implant in a Dog: Histologic and Immunohistochemical Study. M. Vascellari, E. Melchiotti and F. Mutinelli. Istituto Zooprofilattico Sperimentale delle Venezie, Histopathology Department, Viale dell'Universita 10, 35020 Legnaro (PD), Italy. *Vet Pathol* 43:545-548 (2006). www.vetpathology.org
74. Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. Vascellari M, Melchiotti E, Bozza MA, Mutinelli F. Istituto Zooprofilattico Sperimentale delle Venezie, Histopathology Department, Viale dell'Universita 10, 35020 Legnaro (PD), Italy. *J Vet Med A Physiol Pathol Clin Med*. 2003 Aug;50(6):286-91. www.ncbi.nlm.nih.gov
75. Histology and Immunohistochemistry of Seven Ferret Vaccination-site Fibrosarcomas. J. S. Munday, N. L. Stedman and L. J. Richey. Athens Diagnostic Laboratory and Department of Veterinary Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA. *Vet Pathol* 40:288-293 (2003). www.vetpathology.org
76. Practical significance of rabies antibodies in cats and dogs. Michel F. Aubert. Centre national d'études vétérinaires et alimentaires, Laboratoire d'études sur la rage et la pathologie des animaux sauvages, Malzéville, France. *Revue Scientifique et Technique* 1992 Sept; 11(3): 735-60. www.ncbi.nlm.nih.gov
77. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986–1996). Elizabeth Hershey, DVM; Karin U. Sorenmo, CMV, DACVIM; Mattie J. Hendrick, VMD, DACVP; Frances S. Shofer, PhD; David M. Vail, DVM, DACVIM. *Journal of the American Veterinary Medical Association*. January 1, 2000, Vol. 216, No. 1, Pages 58-61. avmajournals.avma.org
78. Pulmonary and mediastinal metastases of vaccination-site sarcoma in a cat. D. G. Rudmann, W. G. Van Alstine, F. Doddy, G. E. Sandusky, T. Barkdull and E. B. Janovitz. Genentech, Inc., South San Francisco, CA 94080, USA. *Veterinary Pathology*, Vol 33, Issue 4, Pages 466-469. www.vetpathology.org
79. The potential role of inflammation in the development of postvaccinal sarcomas in cats. Macy DW, Hendrick MJ. School of Veterinary Medicine, Colorado State College, Fort Collins 80523, USA. *Vet Clin North Am Small Anim Pract*. 1996 Jan;26(1):103-9. www.ncbi.nlm.nih.gov
80. Vaccine-associated Rhabdomyosarcoma with Spinal Epidural Invasion and Pulmonary Metastasis in a Cat. H.-W Chang, S.-Y Ho, H.-F Lo, Y.-C Tu, C.-R Jeng, C.-H Liu, F.-I Wang and V. F. Pang. *Vet Pathol* 43:55-58 (2006). www.vetpathology.org
81. Vaccine Site-Associated Sarcoma and Malignant Lymphoma in Cats: A Report of Six Cases (1997–2002). Bruce R. Madewell, VMD, Diplomate ACVIM (Oncology Internal Medicine), Tracy L. Gieger, DVM, Diplomate ACVIM (Internal Medicine), Patricia A. Pesavento, DVM, PhD and Michael S. Kent, DVM, Diplomate ACVIM (Oncology). *Journal of the American Animal Hospital Association* 40:47-50 (2004). www.jaaha.org
82. Adjuvants in Veterinary Vaccines: Modes of Action and Adverse Effects. Anna R. Spickler and James A. Roth. Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA. *Journal of Veterinary Internal Medicine* 2003 May; 17(3): 273–281. apt.allenpress.com
83. Adverse Vaccine Reactions. W. Jean Dodds, DVM. www.noble-leon.com 76. Are we vaccinating too much? Cairn A. Smith, DVM, *Journal of the American Veterinary Medical Association (JAVMA)* August 15, 1995; Vol. 207, No. 4, Pages 421-425.
84. Avoiding Vaccine Reactions in Dogs and Cats. Craig E. Greene. 28th World Congress of the World Small Animal Veterinary Association: October 24 – 27, 2003: Bangkok, Thailand. www.vin.com 78. Feline Postvaccinal Sarcoma: A 2004 Update. *Histovet Surgical Pathology*. www.histovet.com

85. Feline Vaccine-Associated Sarcomas. Barbara E. Kitchell, DVM, PhD, DACVIM. 30 th World Congress of the World Small Animal Veterinary Association: May 11 – 14, 2005: Mexico City, Mexico. www.vin.com/proceedings
86. Human Illness Associated with Use of Veterinary Vaccines. Ruth L Berkelman. *Clinical Infectious Diseases* 2003; 37: 407–414. www.journals.uchicago.edu (Abstract) or www.journals.uchicago.edu (Full Text)
87. Infectious Disease Prevention Change is in the Wind. Richard B. Ford, DVM, MS, DACVIM, DACVPM (Hon). 30 th World Congress of the World Small Animal Veterinary Association: May 11 – 14, 2005: Mexico City, Mexico. www.vin.com/proceedings
88. Injection Site and Vaccine Associated Sarcomas: New Advances for a New Millennium. Gregory K. Ogilvie, DVM, DACVIM (Internal Medicine, Oncology). 29th World Congress of the World Small Animal Veterinary Association: October 6 – 9, 2004: Rhodes, Greece. www.vin.com
89. Update on Feline Fibrosarcoma. Patrick Devauchelle, DVM 27 WSAVA CONGRESS. www.vin.com
84. Vaccination Protocols for Dogs Predisposed to Vaccine Reactions. W. Jean Dodds, DVM *Journal of the American Animal Hospital Association*. May/June 2001, Vol. 37, Pages 211-214. www.noble-leon.com
90. Vaccine-Associated Feline Sarcoma Task Force: Roundtable Discussion - The current understanding and management of vaccine-associated sarcomas in cats. *JAVMA*: June 1, 2005; Vol. 226, No. 11. www.avma.org
91. Vaccine-associated feline sarcomas. Wallace B. Morrison, DVM, MS, DACVIM; Robin M. Starr, DVM, MEd; and the Vaccine-Associated Feline Sarcoma Task Force. Report of the Vaccine-Associated Feline Sarcoma Task Force from the *Journal of the AVMA*, Vol 218, No. 5, March 1, 2001, pp. 697-702. www.avma.org
92. Vaccine-Associated Sarcomas in the Cat. Glenna Mauldin. World Small Animal Veterinary Association World Congress: 2001: Vancouver. www.vin.com
93. Vaccines of the Present and Future. Alice Wolf. Small Animal Veterinary Association World Congress: 2001: Vancouver. www.vin.com
94. 2006 AAHA Canine Vaccine Guidelines, Revised. Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force. www.aahanet.org
95. The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel Report. *Journal of the American Veterinary Medical Association (JAVMA)*. November 1, 2006; Vol. 229, No. 9, Pages 1405-1441. www.aafponline.org
96. Studies on immunosenescence in the dog and cat have suggested a decline in the immune system with age, but the significance of the decline with regard to increased susceptibility, especially to infectious agents, has not been shown ([Schultz, 1984], [Schultz and Conklin, 1998], Campbell et al., 2004 D.J. Campbell, J.M. Rawlings, S. Koelsch, J. Wallace and J.J. Strain et al., Age-related differences in parameters of feline immune status, *Veterinary Immunology and Immunopathology* 100 (2004), pp. 73–80.)
97. It is likely that an effective MLV vaccine will provide a DOI similar to that following natural infection, but it is very unlikely that a vaccine will provide a longer DOI than would be achieved following natural infection. The DOI may persist via immunological memory involving B and T lymphocytes, long-lived plasma cells that continue to produce antibodies for several years ('memory effector B cells') and possibly long-lived 'memory effector T cells' (Schultz and Conklin, 1998).
98. When dogs recover from natural infection/disease due to CDV, CAV-1 or CPV-2, they develop life-long immunity to these diseases. Long-term immunity also develops in cats that have recovered from infection by FPV. Although immunity to the other core feline viruses (FCV and FHV) is less effective (no sterile immunity), immunity from severe disease does persist in most pet cats for years after vaccination (Scott and Geissinger, 1999; Schultz, 1998).
99. <http://www.pharmabiz.com/article/detnews.asp?articleid=55415§ionid=>
100. **“Guidance for Industry, Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications”**, recently produced by the American FDA
101. **Isolation of an Infectious Endogenous Retrovirus in a Proportion of Live Attenuated Vaccines for Pets**, *Journal of Virology*, April 2010, p. 3690-3694, Vol. 84, No. 7. <http://jvi.asm.org/cgi/content/full/84/7/3690>
102. **Retroviruses and cancer** *CURRENT SCIENCE*, VOL. 81, NO. 5, 10 SEPTEMBER

103. **Immune mediated diseases and the association with vaccine reactions have been reviewed by Day (1999, 2006), Pedersen (1999) and the VPC Working Group (2002).**
104. Intervet's datasheet for Nobivac DHPPi: "Immunocompetence [the ability of the body to develop an immune response in the presence of a disease-causing agent antigen] of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress."
105. "Vaccine-Associated Feline Sarcoma Task Force: Roundtable Discussion". *Journal of the American Veterinary Medical Association* 226 (11). 2005.
106. http://www.avma.org/journals/javma/articles_public/vafstf_050601.asp.
107. Hendrick M, Goldschmidt M (1991). "Do injection site reactions induce fibrosarcomas in cats?". *J Am Vet Med Assoc* **199** (8): 968.
108. Kitchell, Barbara E. (2005). "Feline Vaccine-Associated Sarcomas". *Proceedings of the 30th World Congress of the World Small Animal Veterinary Association*.
109. <http://www.vin.com/proceedings/Proceedings.plx?CID=WSAVA2005&PID=10915&O=Generic>.
110. Richards J, Elston T, Ford R, Gaskell R, Hartmann K, Hurley K, Lappin M, Levy J, Rodan I, Scherk M, Schultz R, Sparkes A (2006). "The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel report". *J Am Vet Med Assoc* **229** (9): 1405–41.
111. Munday J, Stedman N, Richey L (2003). "Histology and immunohistochemistry of seven ferret vaccination-site fibrosarcomas". *Vet Pathol* 40 (3): 288–93.
112. Vascellari M, Melchiotti E, Bozza M, Mutinelli F (2003). "Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas". *J Vet Med a Physiol Pathol Clin Med* 50 (6): 286–91.
113. O'Rourke, Kate (2004). "Researchers probe vaccine-associated feline sarcoma". *Journal of the American Veterinary Medical Association* 225 (6). <http://www.avma.org/onlnews/javma/sep04/040915k.asp>.
114. Hershey A, Sorenmo K, Hendrick M, Shofer F, Vail D (2000). "Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996)". *J Am Vet Med Assoc* 216 (1): 58–61. doi:10.2460/javma.2000.216.58.
115. Martin M (2003). "Vaccine-associated fibrosarcoma in a cat". *Can Vet J* 44 (8): 660–3.
116. Chang H, Ho S, Lo H, Tu Y, Jeng C, Liu C, Wang F, Pang V (2006). "Vaccine-associated rhabdomyosarcoma with spinal epidural invasion and pulmonary metastasis in a cat". *Vet Pathol* 43 (1): 55–8. doi:10.1354/vp.43-1-55.
117. Couto S, Griffey S, Duarte P, Madewell B (2002). "Feline vaccine-associated fibrosarcoma: morphologic distinctions". *Vet Pathol* 39 (1): 33–41. doi:10.1354/vp.39-1-33.
118. Hershey A, Dubielzig R, Padilla M, Helfand S (2005). "Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosis". *Vet Pathol* 42 (6): 805–11. doi:10.1354/vp.42-6-805.
119. Eigner, Diane R.. "Feline Vaccine Guidelines". The Winn Feline Foundation.
120. <http://www.winnfelinehealth.org/health/vaccination-guidelines.html#recommendations>.
121. Lappin, Michael R. (2004). "Feline vaccines". *Proceedings of the 29th World Congress of the World Small Animal Veterinary Association*. <http://www.vin.com/proceedings/Proceedings.plx?CID=WSAVA2004&PID=8684&O=Generic>.
122. Kass P, Spangler W, Hendrick M, McGill L, Esplin D, Lester S, Slater M, Meyer E, Boucher F, Peters E, Gobar G, Htoo T, Decile K (2003). "Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats". *J Am Vet Med Assoc* 223 (9): 1283–92. doi:10.2460/javma.2003.223.1283.
123. Z. Deim, N. Pálmai and G. Csérni: Vaccine-associated fibrosarcoma induced by aluminium compound in two cats, *Acta Veterinaria Hungarica*, volume 56 (2008)
124. **Waisbren BA Sr, *Med Hypotheses*; 70(2):346-8. -- 7/13/2007**

125. Cross-Species Contamination of Commercial Serum Proteins, *The Journal of Immunology*, 1979, 122, 2135:
126. **Vaccine Induced Antibodies Against Feline Tissues** Michael R. Lappin, DVM, PhD, DACVIM The Kenneth W. Smith Professor in Small Animal Clinical Veterinary Medicine, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
127. Neurocognitive deficits and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution. *Lupus* 19: 268-279
128. Differential Responses to Smith D Autoantigen by Mice with HLA-DR and HLA-DQ Transgenes: Dominant Responses by HLA-DR3 Transgenic Mice with Diversification of Autoantibodies to Small Nuclear Ribonucleoprotein, Double-Stranded DNA, and Nuclear Antigens. *J. Immunol.* 184: 1085-1091
129. Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?. *Lupus* 18: 575-580
130. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE). *Lupus* 18: 361-363
131. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. *JEM* 205: 3007-3018
132. {alpha}-Actinin Immunization Elicits Anti-Chromatin Autoimmunity in Nonautoimmune Mice. *J. Immunol.* 179: 1313-1321
133. Accelerated Macrophage Apoptosis Induces Autoantibody Formation and Organ Damage in Systemic Lupus Erythematosus. *J. Immunol.* 176: 2095-2104
134. Models of Systemic Lupus Erythematosus: Development of Autoimmunity Following Peptide Immunizations of Noninbred Pedigreed Rabbits. *J. Immunol.* 176: 660-667
135. Key autoantigens in SLE. *Rheumatology (Oxford)* 44: 975-982
136. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. *Ann Rheum Dis* 64: 444-448
137. Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: relation of cytokine pattern to disease duration. *Lupus* 13: 490-500
138. Deocharan, B, Qing, X, Beger, E, Putterman, C (2002). Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies. *Lupus* 11: 865-871
139. Lowering anti-dsDNA antibodies--what's new?. *Lupus* 11: 885-894
140. Molecular mimicry: anti-DNA antibodies may arise inadvertently as a response to antibodies generated to microorganisms. *Int Immunol* 13: 1099-1107 [
141. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. *Proc. Natl. Acad. Sci. USA* 97: 1184-1189
142. Lupus Nephritis. *J. Am. Soc. Nephrol.* 10: 413-424 "Infective agents, including historically tuberculosis and more recently retroviruses, have been considered as candidates for the provocation of the lupus syndrome; however, there is no convincing evidence of their participation in human disease."
143. <http://www.vetinfo.com/dencyclopedia/dehod.htm>,

144. The Merck Manual of Diagnostics and Therapy, sixteenth edition.
145. DVM vaccine roundtable, Safety, efficacy heart of vaccine use; experts discuss pros and cons. *DVM magazine*, December 1988.
146. Marek's disease vaccines cause temporary U-lymphocyte dysfunction and reduced resistance to infection in chicks" *Avian Pathology*, Vol 21, issue 4, Dec 1992, pages 621-631.)
147. JAVMA Vol 214, No 1, January 1 1999. fatal outbreak of salmonellosis in a breeding cattery following the use of a high titre modified live panleucopaenia virus vaccine
148. *Cancer Research* 30, October 1970, 'Spontaneous Development of Mammary Adenocarcinoma following Prolonged Immunosuppression in the Dog'.
149. (Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination, *Mediators of Inflammation*, 12(4), 203-207 (August 2003)).
150. Effects of Vaccines on the Canine Immune System", (Tom R. Phillips, Jean L. Jensen, Michael J. Rubino, Wen C. Yang and Ronald D. Schultz, *Can J Vet Res* 1989; 53: 154-160)
151. JAVMA, Vol 207, No 4, August 15, 1995 – Current Concepts, are we vaccinating too much?
152. JFM Series A, August 2003, vol 50, no 6, pp 286-291
153. Neginia luP, Comparative study of auto-antibody formation following immunization with different types of vaccines. *ZH Mikrobiol Epidemiol Immunobiol* 1980 May; (5): 69-72.
154. Romanov, UA et al, Role of auto-immune processes in the pathogenesis of post vaccinal lesions of the nervous system. *ZH Mikrobiol Epidemiol Immunobiol* 1977 Oct; 10: 80-93.
155. Mark of the Beast, Dr Patricia Monahan Jordan, www.jordanmarkofthebeast.com
156. IARC International Agency for Research on Cancer; Summaries and Evaluations Surgical Implants and Other Foreign Bodies 1999 Feb 23; 74:24305-310.
157. Smith, G.R. and S. Missailidis, Learning from cancer: The adaptive growth, wound and immune responses. *Gene Therapy and Molecular Biology*, 2009. 13(A): p. 158-185.
158. The Journal of Veterinary Internal Medicine, Vol 10, No 5 (September October) 1996, 'Vaccine Associated Immune Mediated Haemolytic Anaemia (IMHA) in the Dog'
159. Dog World, USA, March 1995, Dr Jean W Dodds, 'Dysfunction in the immune system can compromise the body's entire line of defense'.
160. Concise Oxford Veterinary Dictionary, Oxford University Press, 1988.
161. Detection of Parvovirus B19 Capsid Proteins in Lymphocytic Cells in Synovial Tissue of Autoimmune Chronic Arthritis, *Mod Pathol* (2003), 16(8):811-817
162. In Practice, Vol 20 No 2, Feb 1998, Michael Day
163. British Veterinary Journal (May 1995, Bell, Carter, May and Bennett)
164. *Am Coll Vet Intern Med*, 2000; 14: 381
165. JAVMA, Vol 207, No 4, August 15, 1995 – Current Concepts, are we vaccinating too much?
166. Grene, CE, ed, Appel MJ, *Canine Distemper in Infectious Diseases of the Dog and Cat*, 2nd edition, Philadelphia: WB Saunders, 1998: 9-22
167. *Veterinary Record* during 1992 (130, 27-30)
168. Braund's Clinical Neurology in Small Animals: Localisation, Diagnosis and Treatment, IVIS
169. Brewer, 199; Berendt 2002
170. What Vets Don't Tell You About Vaccines; Shock to the System, O'Driscoll, Abbeywood Publishing.
171. *Dig Dis Sci*, 2000, Apri; 45(4) 723-9
172. *Toxicol Environ Chem* 2008 90(5):997-1008
173. JAVMA, Vol 207, No 4, August 15, 1995 – Current Concepts, are we vaccinating too

much?

174. Commonwealth Department of Health, National Health and Medical Research Council (NHMRC), 1954 – 1986, Report of the Session, No. 38 – 101.
175. Ravel G, Christ M, Horand F, Descotes J, 2004, Autoimmunity, environmental exposure and vaccination: is there a link? , *Toxicology*, 196(3) : 211-6, Mar 15.
176. Food and Drug Administration, 1982 as cited in Kirby, 2005, Evidence of Harm, St. Martins Griffin, New York.
177. <http://www.wsava.org/SAC.htm>
178. Hustead, D.R. 2001. What you can and cannot learn from reading a vaccine label. *Veterinary Clinics of North America: Small Animal Practice*. Vol 31, No.3, May, 539- 556.
179. Day, M.J. 2006. Vaccine side effects: Fact and fiction. *Veterinary Microbiology*. 117, 51-58.
180. Day, M.J. Ageing, immunosenescence and nflammageing in the dog and cat. *J Comp Pathol*. (Epub ahead of print): [http://www.ncbi.nlm.nih.gov/pubmed/20005526?](http://www.ncbi.nlm.nih.gov/pubmed/20005526?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2)
181. Ballerini, Rico B et al., Neurological Complications of Vaccination With Special Reference to Epileptic Syndrome *Riview Neurol*, Jul-Aug 1973; 43: 254-258.
182. "Encephalitis following vaccination against distemper and infectious hepatitis in the dog" "A 4-months-old, male, healthy dog developed CNS-symptoms 10 days after the second vaccination with live, attenuated distemper and canine hepatitis virus." G. Bestetti¹, et al, *Acta Neuropathologica Volume 43, Numbers 1-2 / 69-75 -- 1/1/1978* (Brewer, 199; Berendt 2002).
183. "Disorders in the Murine Chromosome Apparatus Induced By Immunization with a Complex of Anti-viral Vaccines" "Immunization of mice with a number of live virus vaccines (poliovaccine, smallpox vaccine, measles vaccine) given consecutively at 14-day intervals resulted in increased frequency of chromosomal aberrations in bone marrow cells of the animals after the completion of the entire vaccination course (14 and 30 days after the last vaccination). Measles vaccine and, particularly, smallpox vaccine exert a significant harmful effect on the karyotype of the bone marrow cells. " **Cherkeziia, SE, et al, *Vopr Virusol, 1979 Sept Oct, (5):547-550 -- 1/1/1900***
184. "Neurologic complications of smallpox vaccine" "A variety of neurologic complications of smallpox vaccination have been reported, including encephalitis, transverse myelitis, meningitis, and polyneuritis" **Lanska, D, *Meldink.com: neurology -- 1/1/1900***
185. The question of encephalitis following vaccination was investigated by the League of Nations, and on August 27, 1928, the League published a report on the situation. The report stated: "The post-vaccinal encephalitis with which we are dealing has become a problem of itself . . . a new, or at least previously unsuspected or unrecognized risk attaches to vaccination. . . "
186. *The Journal of the American Medical Association on April 2, 1937*: "A multiplicity of untoward sequelae have been observed in patients treated with immune serum...The common symptomatology includes fever, urticaria, erythema, oedema, lymphadenoma, arthralgia, smothering sensations, headache, nausea and vomiting. Occasionally there are more serious and lasting manifestations such as peripheral neuritis, epididymitis and orchitis."
187. The April, 1941, issue of the Naval Medical Bulletin reports on the results of tests on 20,000 recruits at the Naval Training Station at San Diego, California. It states: "All were found free of syphilis, and were then confined. These men were vaccinated against smallpox. Those who did not show 'successful' vaccination were re-vaccinated. The experiment showed that more of these developed syphilis from the smallpox vaccination than the percentage who developed syphilis from all causes in the civilian population in the United States."
188. "Fatal Myocarditis after vaccination against smallpox. Report of a case." Finlay-Jones LR, *N Engl J Med*. 270:41-2. -- 1/1/1964
189. "Diabetes insipidus after Smallpox vaccination." Polster, H., *Z Aerztl Fortbild (Jena)*, 60:429-432 -- 4/1/1966
190. "Fatal Acute Myocarditis After Smallpox Vaccination." Larbre F, et al, *Pediatric*. (3):345-50 -- 5/1/1966
191. "Purulent meningitides Following Smallpox Vaccination. On the Problem of Post-

- Vaccinal Decrease of Resistance." Stickl, H, et al, *Deutsch Med Wschr*, 91:1307-1310 -- 7/22/1966
192. "Skin complications of smallpox vaccination" Copeman, PW., *Practitioner*;197(182):793-800 -- 12/1/1966
 193. "Encephalopathy after vaccination against smallpox with permanent sequel--diabetes insipidus " Palmar I, Kaljalovic R, et al, *Vojnosanit Pregl*;29(5):242-4 -- 5/1/1972
 194. "Encephalitis following smallpox vaccination" Salwa S, *Wiad Lek.* 1; 26(3):215-9. -- 2/1/1973
 195. "Neuromyelitis Optica: Severe Demyelination Occurring Years After Primary Smallpox Vaccinations." Adams, JM et al, *Riv Neurol*, 43:254-258 -- 8/1/1973
 196. "Cytogenetic characteristics of the vaccination process in children, primarily vaccinated against smallpox" "An increased rate of chromosome aberrations in the peripheral blood lymphocytes was observed in children between 1 and 2 1/2 years of age beginning at 4 days after vaccination." Frolov AK, et al, *Vopr Virusol.* (1)83-7 -- 2/1/1975
 197. Frequency of acrocentric chromosomal associations in children immunized with smallpox vaccine" "The frequency of associations of acrocentric chromosomes (AAC) diminished on the 7th day after vaccination in children primary vaccinated, primary revaccinated and secondary revaccinated against smallpox." Frolov AK, et al, *Tsitologija.* (10):1177-83 -- 10/17/1975
 198. "Nine hundred and thirty-eight reports of adverse reactions of smallpox vaccination in Australia between 1960 and 1976... Paradoxically, of eight reports of cardiac complications, seven concerned males." Feery, BJ, *Med J Aust.* 6;2(6):180-3 -- 8/1/1977
 199. "Danger of Sunburn Following Vaccination." "A case of disseminated vaccinia is presented. It is suggested that patients with sunburn may be susceptible to the complications of smallpox vaccination." Edwards, K, *Papua New Guinea Med J*, 20(4):203 -- 12/1/1977
 200. "An Increased Frequency of Chromosomal Changes and SCE's in Cultured Lymphocytes of 12 Subjects Vaccinated Against Smallpox." "Summary An increased frequency of chromosomal changes and sister chromatid exchanges was detected in 10 women 7 days after smallpox vaccination" Knuutila, S et al, *Hum Genet*, 41(1):89-96 -- 2/23/1978
 201. "Plexus paresis and smallpox vaccination" "Paresis of the left side upper plexus brachialis is diagnosed to a boy of 2; 8 years. The trouble appeared after a smallpox vaccination," Berger E, *Pediatr Padol*; 14(4): 449-53. -- 1/1/1979
 202. "Leiomyosarcoma in a smallpox vaccination scar: case report and review of literature" "Including this case, only five have been reported. This is the first report of a leiomyosarcoma arising in a smallpox vaccination scar." P. Sendi et al, *European Journal of Plastic Surgery* Volume 20, Number 2 / 98-100 -- 3/1/1997
 203. "The Smallpox Vaccine and Postvaccinal Encephalitis" "Before we become complacent with the idea that we will respond to a bioterrorism attack with a mass immunization program for smallpox, it is important to be reminded of the risk and clinical manifestations of postvaccinal encephalitis... The first case of postvaccinal encephalitis as a complication of the Jennerian cowpox inoculation was observed in 1905. A century later, there is no effective therapy." Karen L. Roos, et al, *Semin Neurol* 22: 095-098 -- 1/1/2002
 204. Smallpox vaccination: Risk considerations for patients with atopic dermatitis" "Individuals with active or quiescent atopic dermatitis are at increased risk for vaccinia (small pox) complications." Renata J. M. Engler MD, et al, *Journal of Allergy and Clinical Immunology* Volume 110, Issue 3 , Pages 357-365 -- 9/1/2002
 205. "Encephalitis Complicating Smallpox Vaccination" "Postvaccinal encephalitis is a complication of this vaccine. The clinical presentation, course, neuroimaging findings, and spinal fluid abnormalities are similar to a disorder that physicians are familiar with, acute disseminated encephalomyelitis." Augusto Miravalle, et al, *Arch Neurol*;60:925-928 -- 1/1/2003
 206. "A Risk of serious complications and death from smallpox vaccination:" "Results: The life-threatening complications of post-vaccinial encephalitis and vaccinia necrosum were at least 3 and 1 per million primary vaccinations, respectively. Twenty-nine percent of vaccinees with post-vaccinial encephalitis died and 15% with vaccinia necrosum died." Tomás J Aragón, *BMC Public Health*, (3) 26 -- 1/1/2003
 207. "US Military Smallpox Vaccination Program Experience" "Results: ... One case of

- encephalitis and 37 cases of acute myopericarditis developed after vaccination." John D. Grabenstein, RPh, PhD; et al, JAMA. 289:3278-3282 -- 1/1/2003
208. "Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel" "Conclusion: Among US military personnel vaccinated against smallpox, myopericarditis occurred at a rate of 1 per 12 819 primary vaccinees. Myopericarditis should be considered an expected adverse event associated with smallpox vaccination." Jeffrey S. Halsey, et al, JAMA. 289:3283-3289 -- 1/1/2003
209. "Myocarditis after Smallpox Vaccination: A Case Report" "A 20-year-old airman (US Air Force) developed myocarditis 8 days after smallpox vaccination. He was treated with nonsteroidal anti-inflammatory agents, and his symptoms promptly resolved. However, post-vaccinal myocarditis can lead to serious complications and even death." G. Saurina, et al, Clinical Infectious Diseases, volume 37 (2003), pages 145–146 -- 1/1/2003
210. "The Ocular Complications of Smallpox and Smallpox Immunization" "Conclusions: Folliculitis is a common and benign eruption observed in vaccinia-naive adult volunteers following smallpox vaccination." Thomas R. Talbot, MD, MPH, et al, JAMA ;289:3290-3294 -- 1/1/2003
211. "Smallpox Vaccination and Adverse Reactions . Guidance for Clinicians" "Adverse reactions that might require further evaluation or therapy include inadvertent inoculation, generalized vaccinia (GV), eczema vaccinatum (EV), progressive vaccinia (PV), post-vaccinal central nervous system disease, and fetal vaccinia." Joanne Cono, M.D.1, et al, CDC, MMWR; 52(RR04);1-28 -- 2/21/2003
212. Cardiac adverse events following smallpox vaccination in the US. (Market Research Studies). Biomedical Market Newsletter March 31, 2003
213. During Jan. 24-March 21, 2003, smallpox vaccine was administered to 25,645 civilian healthcare and public health workers in 53 jurisdictions, as part of an effort to prepare the US in the event of a terrorist attack using smallpox. Seven cases of cardiac adverse events have been reported among civilian vaccinees since the beginning of the smallpox vaccination program. In addition, 10 cases of myopericarditis have been reported among military vaccinees. This report summarizes data on the seven cases reported among civilians and provides background information on recent military vaccinees. Although a causal association between vaccination and adverse cardiac events in the civilian population is unproven, as a precautionary measure, CDC recommends that persons with physician-diagnosed cardiac disease with or without symptoms (e.g., previous myocardial infarction, angina, congestive heart failure, or cardiomyopathy) be excluded from vaccination during this smallpox preparedness program. The CDC, FDA and state health departments are conducting surveillance for vaccine-associated adverse events among civilian vaccinees. The Department of Defense (DoD) is conducting surveillance for vaccine-associated adverse events among military vaccinees. <http://www.highbeam.com/doc/1G1-100141025.html>
214. "On March 25, an Army National Guardsman aged 55 years with a history of smoking and treatment for hyperlipidemia was found unresponsive in a vehicle 5 days after receiving smallpox vaccine and two other inactivated vaccines. He was resuscitated but died the next day." Staff, CDC, Morbidity & Mortality Weekly Report -- 4/17/2003
215. "A man aged 29 years had ILI symptoms during the same week of primary smallpox vaccination. At the time of smallpox vaccination on March 8, he also received five other inactivated vaccines; 19 days after vaccination, he sought treatment at an ED for dyspnea while lying flat. On March 28, he was hospitalized and had myopericarditis diagnosed based on ECG findings and elevated troponin I and CK-MB." Staff, CDC, Morbidity & Mortality Weekly Report -- 4/17/2003
216. "Adverse Events Following Smallpox Vaccination - United States, 2003" "The 14 patients with myocarditis and/or pericarditis ranged in age from 21 to 33 years. Severity ranged from mild (no ECG or echocardiogram changes) to severe (congestive heart failure), with onset 7 to 19 days after vaccination." Staff, CDC, Morbidity & Mortality Weekly Report -- 4/17/2003
217. "Dermatofibrosarcoma protuberans occurring in a smallpox vaccination scar" "Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive, rarely metastatic, spindle cell tumor. Trauma has been associated with its development. Since the 1940s, malignant tumors have been described to occur in sites of smallpox vaccination scars." Justin J. Green MD, et al, Journal of the American Academy of Dermatology Volume 48, Issue 5, Part 2 , Pages S54-S55 -- 5/1/2003
218. "Adverse events occurring after smallpox vaccination" "Nearly one-half of the United States population is vaccinia-naïve and may be at risk for development of serious adverse events... In the 1960s, death occurred approximately once in every million primary vaccinations, with fatalities

resulting from progressive vaccinia, postvaccinial encephalitis, and eczema vaccinatum.... In today's population, death rates might be higher because of the increased prevalence of immune deficiency and atopic dermatitis." J. Michael Lane MD, MPH, et al, Seminars in Pediatric Infectious Diseases ,Volume 14, Issue 3, Pages 189-195 -- 7/1/2003

219. "Myocarditis: the unexpected return of smallpox vaccine adverse events" "The evidence that myocarditis is caused by the N smallpox vaccination is compelling because the classic tenets of causality have been fulfilled. " Staff, Lancet, Vol 362 -- 10/25/2003
220. "Cardiac Dysrhythmia following Smallpox Vaccination" Timothy J. Whitman, et al, Clinical Infectious Diseases, volume 37 (2003), pages 1579–1580 -- 11/7/2003
221. "Urticaria, Exanthems, and Other Benign Dermatologic Reactions to Smallpox Vaccination in Adults" "Rashes appeared 6-19 days after vaccination and had 5 different clinical presentations. Five volunteers had urticarial rashes that resolved within 4-15 days, 1 had an exanthem that lasted 20 days, and 1 each presented with folliculitis, contact dermatitis, and erythematous papules found only on the hands and fingers. Volunteers reported pruritus, tingling, and occasional headaches." Richard N. Greenberg,, Clinical Infectious Diseases, volume 38 pages 958–965 -- 1/1/2004
222. "Smallpox vaccination and myopericarditis: a clinical review" "If a widespread vaccination program is undertaken in the future, many more cases of post-vaccinial myopericarditis could be seen. Practicing physicians should be aware that smallpox vaccine-associated myopericarditis is a real entity." Dimitri C. Cassimatis, MD, et al, J Am Coll Cardiol, 43:1503-1510 -- 1/1/2004
223. "Myopericarditis following Smallpox Vaccination" "Fifty-eight males and one female aged 21–43 years with confirmed or probable acute myopericarditis were detected following vaccination of 492,730 US Armed Forces personnel from December 15, 2002, through September 30, 2003." Mark K. Arness, et al, American Journal of Epidemiology 160(7):642-651 -- 1/1/2004
224. "Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination" "CONCLUSIONS: Post-vaccinial myopericarditis should be considered in patients with chest pain within 30 days after smallpox vaccination. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. " Robert E. Eckart, DO, et al, J Am Coll Cardiol, 44:201-205 -- 1/1/2004
225. "Smallpox: Clinical Features, Prevention, and Management" "The vaccine may cause moderate to severe adverse events such as eczema vaccinatum, progressive vaccinia, and generalized vaccinia. CONCLUSIONS: The balance between the risks and benefits of mass vaccination in prevention of an epidemic is not clear. " Roy Guharoy, PharmD FCP FCCP FASHP, The Annals of Pharmacotherapy: Vol. 38, No. 3, pp. 440-447 -- 1/30/2004
226. "Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004" "Serious neurologic adverse events, such as postvaccinial encephalitis, Bells palsy, and Guillain-Barré syndrome, occurred in accordance with expected ranges." James J. Sejvar, MD, JAMA :94:2744-2750 -- 1/1/2005
227. "Smallpox Vaccine and Adverse Reproductive Health Outcomes in Military Service Members" "As a live virus product, smallpox vaccine has resulted in fetal vaccinia when administered to pregnant women. This perinatal infection most often results in pregnancy loss or neonatal death; .. At least as concerning as pregnancy loss, and increased risk of birth defects can be extraordinarily alarming to prospective parents. Smallpox vaccination given during pregnancy has been associated with birth defects, specifically club foot malformations..." Ryan, Margaret A, NAVAL HEALTH RESEARCH CENTER SAN DIEGO CA -- 1/1/2005
228. "Smallpox Vaccine and Adverse Reproductive Health Outcomes in Military Service Members" "Currently, with the exception of the passive Vaccine Adverse Event Reporting System (VAERS) for short-term outcomes, there is no structured system to evaluate reproductive health effects of vaccinations." Ryan, Margaret A, NAVAL HEALTH RESEARCH CENTER SAN DIEGO CA -- 1/1/2005
229. "Adverse Events Associated With Smallpox Vaccination in the United States, January-October 2003" "Results... A total of 590 adverse events (72%) were reported within 14 days of vaccination... One hundred adverse events (12%) were designated as serious, resulting in 85 hospitalizations, 2 permanent disabilities, 10 life-threatening illnesses, and 3 deaths." Christine G. Casey, et al, JAMA. 294:2734-2743 -- 10/1/2005

230. "Frequency of Adverse Events after Vaccination with Different Vaccinia Strains." "CONCLUSIONS: Previous analyses of smallpox vaccination policies, which rely on the commonly assumed value of one death per million vaccinations, may give serious underestimates of the number of deaths resulting from vaccination." Kretzschmar M, et al, *PloS Med*; 3(8) -- 8/22/2006
231. "Adverse Reactions: Adverse reactions caused by smallpox vaccination range from mild and self-limited to severe and life-threatening. Certain smallpox vaccine reactions are similar to those caused by other vaccines (e.g., high fever, anaphylaxis, and erythema multiforme [EM]). Other adverse reactions specific to smallpox vaccination include inadvertent inoculation, ocular vaccinia, generalized vaccinia (GV), eczema vaccinatum (EV), progressive vaccinia (PV), postvaccinial encephalopathy (PVE) and encephalomyelitis (PVEM), and fetal vaccinia. Vaccinia-specific complications can occur among vaccinees or their contacts who have been inadvertently inoculated with vaccinia." "Other Vaccine-Specific Adverse Events: Less frequently reported adverse events temporally associated with after smallpox vaccination include myocarditis, pericarditis, precipitation of erythema nodosum leprosum or neuritis among leprosy patients, and osteomyelitis (sometimes confirmed by recovery of vaccinia virus). Reported skin changes at the vaccination scar have included malignant tumors (e.g., melanoma, discoid lupus, and localized myxedema as a symptom of Graves disease). Reported neurologic complications after smallpox vaccination include transverse myelitis, seizures, paralysis, polyneuritis, and brachial neuritis." National Guidelines Clearinghouse -- 3/21/2007
232. Smallpox vaccination and ischemic coronary events in healthy adults." "Although smallpox vaccine-associated myopericarditis has been reported, the risk of cardiac ischemic events remains uncertain." Eckart RE, et al, *Vaccine*.;25(50):8359-64. Epub 2007 Oct 17. -- 12/5/2007
233. "Occurrence of a basal cell carcinoma and dermatofibroma in a smallpox vaccination scar." Curry JL, et al, *Dermatol Surg*.;34(1):132-3; discussion 133-4. -- 1/1/2008
234. "Persistence of vaccinia at the site of smallpox vaccination." "Persistence of vaccinia at vaccination sites may help determine the risk associated with secondary transmission. Culture, PCR, and antigen detection were performed on serial vaccination site swab specimens. On day 21 after vaccination, 37% of volunteers were culture positive, most of whom had received vaccine for the first time." Cummings JF, et al, *Clin Infect Dis*.;46(1):101-2. -- 1/1/2008
235. "Occurrence of a basal cell carcinoma and dermatofibroma in a smallpox vaccination scar." Curry JL, et al, *Dermatol Surg*.;34(1):132-3; discussion 133-4. -- 1/1/2008
236. "Mystery Of Potentially Fatal Reaction To Smallpox Vaccine Solved" "Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine. The research, conducted in mouse models, was funded under a special research network created by the National Institutes of Health in 2004." *ScienceDaily* -- 5/25/2009
237. **Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004, JAMA.** 2005;294:2744-2750,
238. "Very rarely, yellow fever vaccine-associated neurotrpic disease (YEL-AND) has been reported following vaccination, with sequelae or with fatal outcomes in some cases. Clinical features have appeared within one month of vaccination and include high fever with headache that may progress to include one or more of the following: confusion, encephalitis/encephalopathy, meningitis, focal neurological deficits, or Guillain Barre syndrome." **Package insert, Sanofi Pasteur, Manufacturer -- 1/1/1900**
239. **"Coincidence of virus encephalitis and measles-mumps vaccination"** "A 15-month-old girl developed meningoencephalitis 7 days after measles/mumps vaccination, and died 3 days later." Jorch, G. et al, *Monatsschr Kinderheilkd* 1984; 132(5):299-300 -- 1/1/1900
240. **"Relapsing Neuropathy due to tetanus toxoid."** "Summary: A unique case history is presented of a 42-year-old patient who has suffered three episodes of a demyelinating neuropathy, each of which followed an injection of tetanus toxoid." Pollard, JD; Selby, G, *Journal of the Neurological Sciences*, 1978, 37: 113-125 -- 1/1/1900
241. **"But Doctor, About That Shot...The Risks of Immunizations and How to Avoid Them"** "Complications occurring following tetanus vaccinations include: high fever, pain, recurrent abscess formation, inner ear nerve damage, demyelinating neuropathy (degenerative condition of the nervous system), each of which followed an injections of tetanus toxoid." Robert S. Mendelsohn, M.D., *Journal of Neurological Sciences*, 1978 -- 1/1/1900

242. "Optic neuritis and myelitis following rubella vaccination" Kline L, Margulies SL, *Arch Neurol* 1982;39:443-4 -- 1/1/1900

"A case of fatal tuberculous meningoencephalitis after typhoid-paratyphoid vaccination." Camba R, *Rass Med Sarda*;55(5-6):186-96. -- 5/1/1953

243. "Etiology of acute encephalomyelitis after rabies vaccination." Piskareva NA, *Vopr Virusol*; 1(6):47-50. -- 11/1/1956 "Experimental studies on paralysis after antirabies vaccination. I. Histological studies on acute demyelinating encephalomyelitis in guinea pigs." Shiina T, et al, *Jpn J Microbiol*; 2(2):187-96. -- 4/1/1958

244. "Clinical picture of postvaccinal encephalitis after rabies vaccination and sequelae." Uchimaura Y, et al, *Nervenarzt*; 29(7): 303-7. -- 7/1/1958

245. "Encephalitis after yellow fever vaccination" "...is concluded that there is a cause and effect relationship between the administration of yellow fever vaccine and the occurrence of subsequent encephalitis in this infant." Morris Feitel M.D, *Pediatrics* Vol. 25 No. 6, pp. 956-958 -- 6/1/1960

246. "Death of an infant in hyperthermia after vaccination" "Death following hyperpyrexia and coma of rapid onset nine days after vaccination of an infant is reported. Death appeared to be due to overwhelming vaccinia infection without encephalitis." Apostolov, K., et al, *J Clin Pathol*. 14(2): 196-197 -- 3/1/1961

247. "On a Case of Benign Acute Cerebellar Ataxia in Childhood." Provvidenza, G et al, *Arch Ital Sci Med Trop*, 43:189-194 -- 4/1/1962

248. "Transient cerebellar ataxia following the administration of attenuated oral antipoliomyelitis vaccine (Sabin types II and III)." Colarizi A, et al, *Riv Ist Sieroter Ital.*; 38:1-12. -- 1/1/1963

249. "2 cases of hypoglycemic coma in the immediate sequelae of vaccination." Sirand L, *Pediatric*. 1963; 18:581-2. -- 1/1/1963

250. "Myelitis as a complication following rabies vaccination." Gospavic J, et al, *Srp Arh Celok Lek*; 91:141-8. -- 2/1/1963

251. "Coma revealing an acute leukosis in a child, 15 days after an oral antipoliomyelitis vaccination. Anatomoclinical study and reflections on cerebral lesions in acute leukoses" Castan P and Dehing, J, *Acta Neurol Belg*, 65:349-367 -- 5/1/1965

252. "Multiple sclerosis and vaccination." Miller H, et al, *Br Med J.*; 2(5546): 210-3. -- 4/1/1967

253. "The management of meningoencephalitis following rabies vaccination" Klemm D, et al, *Med Klin*;63(34):1354. -- 8/1/1968

254. "Morphological changes in the central nervous system in post-vaccinal encephalomyelitis developing after chickenpox vaccination in children" Ravkina LI, et al, *Zh Nevropatol Psikhiatr Im S S Korsakova*. 1970; 70(10): 1465-71. -- 1/1/1970

255. "Incomplete transverse myelitis following rabies duck embryo vaccination." Harrington RB, et al, *JAMA*; 216(13):2137-8. -- 6/1/1971

256. "Encephalitis after rabies vaccination" Kreiner R, Seege D, *Psychiatr Neurol Med Psychol (Leipz)*; 23(9): 532-6. -- 9/1/1971

257. "Meningomyelitis after rabies vaccination. Apropos of 3 cases" Giordano C, et al, *Med Trop (Mars)*; 32(4):483-92. -- 7/1/1972

258. "Further Studies of a Simian Virus 40-Like Virus Isolated from Human Brain" "A virus

- similar to simian virus 40 was reisolated from brain homogenates of a patient with progressive multifocal leukoencephalopathy onto cultures of human fetal brain cells." L. P. Weiner, *J Virol.*;10(1): 147-149 -- 7/1/1972
259. "Relapsing encephalomyelitis following the use of influenza vaccine" Yahr MD and Lobo-Antunes, J, *Arch Neurol.* 27(2):182-3. -- 8/1/1972
260. "Hyperacute Allergic Encephalomyelitis: A localised form produced by passive transfer and pertussis vaccine." "Blockade of histamine H1 receptors may reduce mortality in pertussis immunisation-induced encephalopathy in mice." Levine, S et al, *American Journal of Pathology*; 73:247-260 -- 1/1/1973
261. "Panencephalitis Following Measles Vaccination." Cho, CT, et al, *JAMA*, 224:1299 -- 5/28/1973
262. "Encephalitis after administration of live measles vaccine" "In a previously well child with no evidence of pre-existing immunologic defect a fatal encephalitis developed 10 days after administration of measles vaccine." F. Jagdis, et al, *Canadian Medical Association Journal*, Vol 112, Issue 8 972-975 -- 1/1/1975
263. "Letter: Vaccinations in chronic myelosis?" Mohr W, *Dtsch Med Wochenschr* 12; 101(11):430. -- 3/1/1976
264. "Transverse myelitis after diphtheria, tetanus, and polio immunisation." Whittle E, et al, *Br Med J.*; 1(6074): 1450. -- 6/1/1977
265. "Relapsing neuropathy due to tetanus toxoid. Report of a case." "A unique case history is presented, of a 42-year-old patient who has suffered three episodes of a demyelinating neuropathy, each of which followed an injection of tetanus toxoid." Pollard JD, et al, *J Neurol Sci.*; 37(1-2): 113-25. -- 6/1/1978
266. "Meningoencephalitic syndrome following influenza vaccination" "Immunological reactions to non-virus substances of vaccines may be of considerable significance in the pathogenesis of neurological complications after anti-influenza vaccination. A 60 year old female patient with a known allergic diathesis developed a meningoencephalitic syndrome a few hours after vaccination." W. L. Gross, et al, *Journal of Neurology* Volume 217, Number 3 / 219-222 -- 9/1/1978
267. "Acute Meningoencephalitis Immediately after an Influenza Vaccination." Froissart, M. et al, *Lille Med*, 23(8):548-551 -- 10/1/1978
268. "Neurological complications following measles virus vaccination. Evaluation of the cases seen between 1971--1977" "Within 11 days following vaccination with live virus vaccine in Hamburg 18 cases of neurological complications have been observed between 1971--1977, including 2 cases of abortive encephalitis." Allerdist, H, *Monatsschr Kinderheilkd.*;127(1):23-8 -- 1/1/1979
269. "Adverse reactions after pertussis vaccination." "Further analysis of the S group revealed that all but two of their symptoms (fever and encephalopathy) corresponded to the hypoglycaemic syndrome." Hennesen W, et al, *Dev Biol Stand*; 43:95-100. -- 1/1/1979
270. "Encephalitis Developing After Vaccination without a Local Skin Reaction." Naumova, R.P., et al, *Vrach Delo*, (7):114-115 -- 7/1/1979
271. "Acute disseminated encephalomyelitis after influenza vaccination" "A 12-year-old, previously healthy boy was seen with typical signs of acute disseminated encephalomyelitis four days after influenza vaccination" H. Saito, et al, *Archives of Neurology* Vol. 37 No. 9 -- 9/1/1980
272. "A new Model of Multiple Sclerosis; Experimental Vaccinia Infection in the Monkey" "The results show that vaccinia virus induces two forms of infection in the central nervous system, i.e. choriomeningitis and demyelination disease." Simon, J et al, *Forsch Med*, 98(41):1607-1611 -- 11/6/1980
273. "A SV40-like virus was isolated from the brain of a patient with progressive multifocal leukoencephalopathy." Scherneck S, et al, *Acta Virol.*;25(4):191-8 -- 7/1/1981
274. "Murine model for pertussis vaccine encephalopathy: linkage to H-2" "Local, systemic and neurological complications have been observed following pertussis (whooping cough) vaccination in children^{1,2}. These often occur soon after primary or secondary immunization. The neurological syndrome ranges from minor irritability to convulsions, coma, and on rare occasions death." L. Steinman, et al, *Nature* 299, 738 - 740 -- 10/21/1982

275. "Vaccinia (small pox) virus in postvaccinal encephalitis." "In 3 postvaccinal encephalitis cases the virus was present in brain and in a case of encephalomyelitis--in the spinal cord. These results confirmed the participation of vaccinia virus in the pathogenesis of postvaccinal encephalitis." Gurvich EB, et al, *Acta Virol*;27(2):154-9 -- 3/1/1983
276. "Measles, measles vaccination, and risk of subacute sclerosing panencephalitis (SSPE)" "Occurrence of subacute sclerosing panencephalitis (SSPE) in some children who were vaccinated against measles could be explained by incomplete vaccine efficacy Measles, measles vaccination, and risk of subacute sclerosing panencephalitis (SSPE) " N Zilber, *Neurology*, Vol 33, Issue 12 1558-1564 -- 12/1/1983
277. "Acute necrotic myelopathy associated with influenza vaccination." Graus F, et al, *Lancet*; 1(8545):1311-2. -- 6/1/1987
278. "Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination" "Encephalitis and polyneuritis occurring after rabies vaccination are believed to be immunologically mediated. We studied antibody responses to neural antigens in 36 patients with major neurologic complications, 25 with minor complications, and 39 with no complications after immunization with a brain-derived, Semple rabies vaccine." T Hemachudha, et al, *New England Journal of Medicine* Volume 316:369-374 , Number 7 -- 2/12/1987
279. "Incidence of Subacute Sclerosing Panencephalitis Following Measles and Measles Vaccination in Japan" "The Japanese Committee for the National Registry of Subacute Sclerosing Panencephalitis (SSPE) confirmed that 215 cases of SSPE occurred" Yoshiomi Okuno, *International Journal of Epidemiology* Volume 18, Number 3 Pp. 684-689 -- 10/1/1988
280. "Acute cerebellar ataxia after influenza vaccination with recurrence and marked cerebellar atrophy." "A 5-year-old, previously healthy girl developed symptoms and signs of acute cerebellar ataxia (ACA) 8 days after having received an influenza vaccination." Saito H, et al, *Tohoku J Exp Med*; 158(1): 95-103. -- 5/1/1989
281. "Acute cerebellar ataxia and facial palsy after DPT immunization" "Since the initial report of Beyers & Moll (1948), numerous cases of seizures and encephalopathy after pertussis immunization or DPT immunization have been reported. We report a 1-year-11-month-old girl with acute cerebellar ataxia and facial palsy after DPT immunization." Katafuchi Y, et al, *No To Hattatsu*. 21(5):465-9. -- 9/1/1989
282. "Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barre syndrome) after immunization with Haemophilus influenzae type b conjugate vaccine." D'Cruz OF, et al, *J Pediatr*; 115(5 Pt 1):743-6. -- 11/1/1989
283. "Encephalitis in a 13-year-old boy following 17D yellow fever vaccine." "We report a case of encephalitis following yellow fever vaccine in a healthy 13 year-old-boy." Schoub BD, et al., *J Infect*; 21(1):105-6. -- 7/1/1990
284. "Cerebellar ataxia following cholera vaccination - case report" "Case reported here is a rare instance of acute cerebellar ataxia occurring after cholera vaccination in a 14 year old girl." Jain, AP, et al, *Neurology India*; 38(6): 629-30 -- 11/1/1990
285. "Varicella and remission of multiple sclerosis." Ross RT, *Lancet*; 337(8736): 300. -- 2/1/1991
286. "Bilateral acute profound deafness after MMR vaccination--report of a case" Koga K, et al, *Nippon Jibiinkoka Gakkai Kaiho*. 94(8):1142-5. -- 8/1/1991
287. "Aseptic meningitis as a complication of mumps vaccination" Sugiura A, et al, *Pediatr Infect Dis J*. (3):209-13 -- 3/10/1991
288. "Ataxia-telangiectasia in a child with vaccine-associated paralytic poliomyelitis." "Vaccine-acquired poliomyelitis developed in a nonimmunized 10-month-old boy. Pohl KR, et al, *J Pediatr*; 121(3): 405-7. -- 9/1/1992
289. "Severe post-vaccination reaction to 17D yellow fever vaccine in Nigeria." "An unusual outbreak of post-vaccination reactions to 17D yellow fever vaccine occurred at Shaki, Nigeria, in May 1987. The patients presented with rapidly progressing swelling of the left arm with associated fever and other constitutional symptoms few hours after inoculation with the vaccine. Some of the patients developed gangrene of the affected limb, five of them went into coma and died." Oyelami SA, et al, *Rev Roum Virol*. 45(1-2):25-30. -- 1/1/1994
290. "Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated

- human encephalitis." "The virulence of a yellow fever (YF) virus (P-16065) isolated from a fatal case of vaccine-associated viral encephalitis was investigated." Jennings AD, et al, *J Infect Dis.*; 169(3):512-8. -- 3/1/1994
291. "Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine" "Seven children with acute disseminated encephalomyelitis (ADEM) after treatment with Japanese B encephalitis vaccine " E Ohtaki, et al, *Journal of Neurology, Neurosurgery, and Psychiatry*, Vol 59, 316-317 -- 1/1/1995
292. "Guillan Barre" "Eight strains of P3/Sabin-related polioviruses were analyzed; four from persistent paralytic poliomyelitis cases classified as vaccine associated, one from a transient paralysis case classified as transverse myelitis, one from a transient paralysis case classified as Guillain-Barre syndrome, one from a transient facial paralysis case," Friedrich F, et al, *Braz J Med Biol Res.*; 28(2):195-200 -- 2/1/1995
293. "Sabin-related poliovirus vaccine strains isolated from transverse myelitis cases in Brazil" F. Friedrich, et al, *Rev. Inst. Med. trop. S. Paulo* vol.37 no.6 São Paulo -- 11/1/1995
294. "Relapsing acute encephalopathy: a complication of diphtheria-tetanus-poliomyelitis immunization in a young boy" J. Mancini, et al, *European Journal of Pediatrics*; Volume 155, Number 2 / 136-138 -- 1/1/1996
295. "A Cluster of Severe Reactions Following Improperly Administered Takeda Japanese Encephalitis Vaccine" H. James Beecham III, et al, *Journal of Travel Medicine* Volume 4 Page 8 -- 3/1/1997
296. "Acute disseminated myelitis after Japanese B encephalitis vaccination. " Fukuda H, et al, *J Neurol Sci.*; 148(1): 113-5. -- 5/1/1997
297. "Rare adverse events associated with oral poliovirus vaccine in Brazil" "The temporal association between the isolation of these strains and the GBS (Guillain Barre Sysdrom), TM (Transverse Myelitis) and FP (Facial Paralysis) suggested that the Sabin vaccine-derived poliovirus strains could also rarely trigger the diseases." F. Friedrich, *Braz J Med Biol Res*, Volume 30(6) 695-703 -- 6/1/1997
298. "MRI in acute disseminated encephalomyelitis following Semple antirabies vaccine" "MRI findings in five patients with acute disseminated encephalomyelitis following vaccination with Semple antirabies vaccine. " J. M. K. Murthy, *Neuroradiology* Volume 40, Number 7 / 420-423 -- 7/1/1998
299. "Neurological complications to vaccination against Japanese encephalitis." Plesner AM, et al, *Eur J Neurol.*; 5(5):479-485. -- 9/1/1998
300. "Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA." "Acute disseminated encephalomyelitis, an inflammatory demyelinating disease of the central nervous system, can occur after viral infections or vaccinations. We report the clinical and neuroimaging findings in a 52-year-old man in whom acute disseminated encephalomyelitis developed after accidental self-injection of an industrial hog vaccine. Acute disseminated encephalomyelitis after accidental injection of a hog vaccine " Dodick DW, et al, *Mayo Clin Proc.* 73(12):1193-5. -- 12/1/1998
301. "Two Human Rabies Cases in Spite of HCDV Vaccination" "She had 4 doses HCDV rabies vaccine but no RIG. She had paresthesia around her lip. She appeared in fear. Hydrophobia, aerophobia and right facial paralysis appeared in patient. Finally, hypersalivation and dyspnea occurred. She died in 32 hours after admission. Postmortem brain biopsy performed and histopathological examination revealed as encephalitis and eosinophilic neuronal necrosis." Aksu HS, *Chemother.* 16-19; 41: abstract no. L-2286. -- 12/1/2001
302. "Neurological adverse events associated with vaccination" "These complications include autism (measles vaccine), multiple sclerosis (hepatitis B vaccine), meningoencephalitis (Japanese encephalitis vaccine), Guillain-Barre syndrome and giant cell arteritis (influenza vaccine), and reactions after exposure to animal rabies vaccine. Seizures and hypotonic/hyporesponsive episodes following pertussis vaccination and potential risks associated with varicella vaccination, as well as vaccine-associated paralytic poliomyelitis following oral poliovirus vaccination, are also described." Piyasirisilp, Sucheep a; Hemachudha, Thiravat b, *Neurology.* 15(3):333-338 -- 6/1/2002
303. "Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the Vaccine Adverse Event Reporting System" "Acute encephalopathy age <18 months, encephalitis (EI), and multiple sclerosis (MS) after vaccination have been reported to VAERS" Robert Ball, et al, *Journal of Clinical Epidemiology* Volume 55, Issue 8, Pages 819-824 --

8/1/2002

304. "Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases"
"Autoimmune inflammatory polyneuropathy (PN) can be triggered by vaccination. We report 3 such cases. A 36-year-old female nurse presented 15 days after a hepatitis B vaccination (HBV) with acute sensory disturbances in the lower limbs. She had severe ataxia but no weakness." Claude Vital, et al, *Journal of the Peripheral Nervous System* Volume 7 Page 163 -- 9/1/2002
305. "Transverse myelitis after vaccination" "Transverse myelitis after vaccination." G. Zaroni, et al, *European Journal of Neurology*; Volume 9 Page 696 -- 11/1/2002
306. "Encephalitis following Purified Chick-Embryo Cell Anti-Rabies Vaccination" "A 32 years old man presented with history of dog bite 1 month back for which he was vaccinated with Rabipur as per schedule (0,3,7,14,30).On the day after the fifth dose of the vaccine, he started having high grade fever with chills and rigors. After 3 days, he developed difficulty in opening the right eye, as well as inability to walk. There was swaying more towards left side. " NS Neki, et al, *JACM*; 4(3): 251-9 -- 1/1/2003
307. "Acute disseminated encephalomyelitis" "a T cell mediated autoimmune response to myelin basic protein, triggered by an infection or vaccination, underlies its pathogenesis. " R K Garg, *Postgraduate Medical Journal*; 79:11-17 -- 1/1/2003
308. "Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child." Hidalgo, Solange M.D.; et al, *Pediatric Infectious Disease Journal*. 22(6):570-572, -- 6/1/2003
309. "Some genetic characteristics of sabin-like poliovirus isolated from acute flaccid paralysis cases in Nigeria" "A total of 34 sabin strains of the poliovirus isolated from 22 children with 60-day follow-up residual acute flaccid paralysis (AFP)" Festus Doyin Adu, *African Journal of Biotechnology* Vol. 2, No. 11, pp. 460-464 -- 11/1/2003
310. "Neurologic complications of immunization." "Individual vaccines can produce systemic or neurologic reactions ranging from minor events, such as pain and erythema at the injection site, to major complications, such as seizures, shock, encephalopathy, or death." Bale JF Jr, *J Child Neurol.*; 19(6): 405-12. -- 6/1/2004
311. "An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines." "Our results, and conclusions by the US Institute of Medicine, suggest an association between serious neurological disorders (life-threatening reactions, hospitalizations, disabilities, deaths, seizures, infantile spasms, encephalitis/encephalopathy, autism, Sudden Infant Death Syndrome (SIDS) and speech disorders) and whole-cell pertussis immunization. " Geier DA, and Geier, MR, *Brain Dev.* 26(5):296-300. -- 8/1/2004
312. **"A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001"** "Results: We found a total of 197 reports of Bell's palsy after receipt of influenza vaccines. The diagnosis was verified for 154 (78.2%), of which 145 (94.2%) had received influenza vaccines alone." **Weigong Zhou, MD, PhD, et al, *Volume 13, Issue 8, Pages 505 – 510 11, -- 8/1/2004***
313. **"Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX."** "Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded." **Kitchener S, *Vaccine*; 22(17-18):2103-5. -- 6/2/2004**
314. **"Autoimmune hazards of hepatitis B vaccine."** "Then, a review is made of data suggesting that HBV is remarkable by the frequency, the severity and the variety of its complications, some of them probably related to a mechanism of molecular mimicry leading to demyelinating diseases, and the others reproducing the spectrum of non-hepatic manifestations of natural hepatitis B." **Girard M, *Autoimmun Rev*; 4(2): 96-100. -- 2/1/2005**
315. **"Demyelinating motor Guillain–Barré syndrome following rubella"**
"Demyelinating motor Guillain–Barré syndrome following rubella" **M. Capasso, et al, *Neurology, Vol. 64, Issue 2, 390 -- 1/25/2005***
316. **"Expression and characterization of a low molecular weight recombinant**

human gelatin: development of a substitute for animal-derived gelatin with superior features." Gelatin is used as a stabilizer in several vaccines. Allergic reactions to gelatins have been reported, including anaphylaxis. These gelatins are derived from animal tissues and thus represent a potential source of contaminants that cause transmissible spongiform encephalopathies." Olsen D, et al, *Protein Expr Purif.*; 40(2):346-57 -- 4/1/2005

317. **"Measles and rubella vaccination of two million Iranians: Complications in vaccinees aged 5–25 years"** "A total of 688 adverse events was reported in 476 vaccine recipients with a female dominance (female to male ratio 2.2). Severe adverse events were noted in 13 cases: seizures within 48 h of vaccination, encephalopathy, flaccid paralysis and anaphylaxis." Parviz Vahdani, et al, *Scandinavian Journal of Infectious Diseases Volume 37, Number 11-12 / 913 – 915* -- 11/1/2005
318. **"Acute encephalitis complicating rubella: a case report from Turkey"** "An 18-year-old patient presented with severe encephalitis. Clinical features included, fever appearing 3 days after a rash covering the face and the trunk, loss of consciousness and myoclonic contractions." Nese Demirturk, et al, *Case Rep Clin Pract Rev*, 7: 186-189 -- 1/1/2006
319. **"An Outbreak of Poliomyelitis Caused by Type 1 Vaccine-Derived Poliovirus in China"** "This is the first polio outbreak in China in over a decade and the first due to VDPV (vaccine derived polio virus)... This outbreak highlights the need to consider risks of paralysis from vaccine-derived strains in development of national poliomyelitis immunization policy." Xiaofeng Liang, et al, *The Journal of Infectious Diseases*, volume 194, pages 545–551 -- 1/1/2006
320. **"Chinese police haul off "bad vaccine" protesters"** "Chinese police hauled off a small group of people on Thursday who... say that their children were vaccinated against Japanese encephalitis B in 2003 in the southern province of Guangdong, and that the vaccine has paralysed their sons and daughters. We were taken away by the police a little while ago, Liang Yongli, father of one of the children, told Reuters by mobile telephone. I don't know where we are but there seem to be lots of people like us here. " Staff, Reuters -- 8/17/2006
321. **"Poliomyelitis: A Case Report of Flaccid Monoparesis after Oral Polio Vaccine"** "This report describes a case of acute flaccid paralysis after administration of oral polio vaccine (OPV). A 4 month-old male patient with the decreased movement of left lower extremity for 1 month was transferred to the Department of Pediatrics. He received OPV with DTaP at 2 months of age. Flaccid paralysis was detected 4 weeks after OPV immunization." Sun Jun Kim, et al, *J Korean Med Sci*; 22:362-4 -- 1/1/2007
322. **"Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases."** "Based on defined criteria, five cases of encephalitis were classified as 'definitely' and one of acute disseminated encephalomyelitis (ADEM) as 'probably' caused by YEL (Yellow Fever Vaccine). Six cases of Guillain-Barre Syndrome (GBS), one of encephalitis, and two of ADEM, were classified as 'suspect' vaccine-associated disease. Laboratory and epidemiological evidence suggests that YEL caused encephalitis." McMahon AW, et al, *Vaccine*.;25(10):1727-34. -- 2/26/2007
323. **"Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom."** "Measles-mumps-rubella (MMR) vaccines containing the Urabe strain of mumps were withdrawn in the United Kingdom in 1992 following demonstration of an increased risk of aseptic meningitis 15-35 days after vaccination. Following introduction of a replacement MMR vaccine (Priorix)... an elevated relative incidence of convulsion was found in the 6- to 11-day period after receipt of Priorix." Miller E, et al, *Am J Epidemiol*.;165(6):704-9. -- 3/15/2007
324. **"Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005."** "During the 2001 yellow fever mass vaccination campaign held in Juiz de Fora, Brazil, 12 cases of aseptic meningitis were temporally associated to yellow fever vaccination." Fernandes GC, et al, *Vaccine*.;25(16):3124-8. -- 4/20/2007
325. **"Nigeria fights rare vaccine-derived polio outbreak"** "Nigeria is fighting a rare outbreak of vaccine-derived polio after 69 children caught the paralysing disease from others who had already been immunised, the World Health Organisation said on Monday." MacInnis L, Reuters -- 10/8/2007
326. **"Safety of Varicella Vaccine after Licensure in the United States: Experience from Reports to the Vaccine Adverse Event Reporting System, 1995–2005"** "There were 25,306 adverse events reported (52.7/100,000 doses distributed); 5.0% were classified as serious (2.6/100,000 doses distributed). Adverse events associated with evidence of vaccine strain VZV included meningitis in patients with concurrent herpes zoster." Chaves, SS, et al., *The Journal of Infectious Diseases* 197:S170–S177 -- 1/1/2008

327. "Vaccine Court: Hepatitis B Shot Caused MS" "But another omnibus proceeding involving Hepatitis B vaccine and autoimmune disorders in adults, including MS, has already been quietly ruling in favor of several petitioners. The most recent case was announced about a week ago. In it, the Court ruled that the victim, an adult female, had contracted a form of demyelinating disease and MS, and eventually died, after receiving the Hepatitis B vaccine series." Kirby, D, Age of Autism -- 2/3/2009
328. Trijzelaar B. Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice- -validation of virus removal and inactivation. *Biotherapy* 1993; 6(2):93-102. PMID 8398576.
329. Vilcek S. Identification of pestiviruses contaminating cell lines and fetal calf sera. *Acta Virol* 2001 Apr;45(2):81-6. PMID 11719986.
330. Barkema HW, Bartels CJ, van Wuijckhuise L, Hesselink JW, Holzhauer M, Weber MF, Franken P, Kock PA, Brusckhe CJ, Zimmer GM. Outbreak of bovine virus diarrhea on Dutch dairy farms induced by a bovine herpesvirus 1 marker vaccine contaminated with bovine virus diarrhea virus type 2. *Tijdschr Diergeneeskd* 2001 Mar 15;126(6):158-65. PMID 11285633.
331. Rolleston WB. Bovine serum: reducing the variables through the use of donor herds. *Dev Biol Stand* 1999;99:79-86. PMID 10404879.
332. Bolin SR, Matthews PJ, Ridpath JF. Methods for detection and frequency of contamination of fetal calf serum with bovine viral diarrhea virus and antibodies against bovine viral diarrhea virus. : *J Vet Diagn Invest* 1991 Jul;3(3):199-203. PMID 1655059.
333. Erickson GA, Landgraf JG, Wessman SJ, Koski TA, Moss LM. Detection and elimination of adventitious agents in continuous cell lines. *Dev Biol Stand* 1989;70:59-66. PMID 2759356.
334. Yanagi M, Bukh J, Emerson SU, Purcell RH. Contamination of commercially available fetal bovine sera with bovine viral diarrhea virus genomes: implications for the study of hepatitis C virus in cell cultures. *J Infect Dis* 1996 Dec;174(6):1324-7. PMID 8940226.
335. Giangaspero M, Harasawa R, Verhulst A. Genotypic analysis of the 5'-untranslated region of a pestivirus strain isolated from human leucocytes. *Microbiol Immunol* 1997;41(10):829-34. PMID 9403511.
336. Harasawa R, Mizusawa H. Demonstration and genotyping of pestivirus RNA from mammalian cell lines. *Microbiol Immunol* 1995;39(12):979-85. PMID 8789057.
337. Stoffregen B, Bolin SR, Ridpath JF, Pohlenz J. Morphologic lesions in type 2 BVDV infections experimentally induced by strain BVDV2-1373 recovered from a field case. *Vet Microbiol* 2000 Nov 15;77(1-2):157-62. PMID 11042409.
338. Meehan JT, Lehmkuhl HD, Cutlip RC, Bolin SR. Acute pulmonary lesions in sheep experimentally infected with bovine viral diarrhoea virus. *J Comp Pathol* 1998 Oct;119(3):277-92. PMID 9807729.
339. Loken T, Krogsrud J, Bjerkas I. Outbreaks of border disease in goats induced by a pestivirus-contaminated orf vaccine, with virus transmission to sheep and cattle. *J Comp Pathol* 1991 Feb;104(2):195-209. PMID 1650802.
340. Yolken R, Dubovi E, Leister F, Reid R, Almeida-Hill J, Santosham M. Infantile gastroenteritis associated with excretion of pestivirus antigens. *Lancet* 1989 Mar 11;1(8637):517-20. PMID 2564059.
341. Potts BJ, Sever JL, Tzan NR, Huddleston D, Elder GA. Possible role of pestiviruses in microcephaly. *Lancet* 1987 Apr 25;1(8539):972-3.
342. Harasawa R. Latent Risk in Bovine Serums Used for Biopharmaceutical Production. <http://www.asmtusa.org/pcsrc/sum02.htm>
343. Levings RL, Wessman SJ. Bovine viral diarrhea virus contamination of nutrient serum, cell cultures and viral vaccines. *Dev Biol Stand* 1991;75:177-81. PMID 1665461.
344. Giangaspero M, Vacirca G, Harasawa R, Buttner M, Panuccio A, De Giuli Morghen C, Zanetti A, Belloli A, Verhulst A. Genotypes of pestivirus RNA detected in live virus vaccines for human use. *J Vet Med Sci* 2001 Jul;63(7):723-33. PMID 11503899.
345. Harasawa R, Mizusawa H. Detection of Pestiviruses from Mammalian Cell Cultures by

the Polymerase Chain Reaction. Proceedings of 3rd Internet World Congress on Biomedical Sciences 1996.12.9-20 Riken, Tsukuba, Japan.

346. Contreras G, Bather R, Furesz J, Becker BC. Activation of metastatic potential in African green monkey kidney cell lines by prolonged in vitro culture. *In Vitro Cell Dev Biol* 1985 Nov;21(11):649-52. PMID 4066602.
347. Levenbook IS, Petricciani JC, Elisberg BL. Tumorigenicity of Vero cells. *J Biol Stand* 1984 Oct;12(4):391-8. PMID 6526826.
348. Furesz J, Fanok A, Contreras G, Becker B. Tumorigenicity testing of various cell substrates for production of biologicals. *Dev Biol Stand* 1989;70:233-43. PMID 2759351.
349. Letter to Sponsors Using Vero Cells as a Cell Substrate for Investigational Vaccines. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Division of Vaccines and Related Products Applications, March 12, 2001. www.fda.gov/cber/ltr/vero031301.htm
350. U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Biologics Evaluation and Research. Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development. <http://www.fda.gov/cber/minutes/0907evolv.txt>
351. Lewis AM Jr. Developing an approach to evaluate the use of neoplastic cells as vaccine substrates. *Dev Biol (Basel)* 2001;106:37-42; discussion 42-3. PMID 11761251.
352. Purcell DF. Pathogenesis of replication competent retroviruses derived from mouse cells in immunosuppressed primates: implications for use of neoplastic cells as vaccine substrates. *Dev Biol (Basel)* 2001;106:187-98; discussion 199, 253-63. PMID 1176123
353. Amosenko FA, Svitkin YV, Popova VD, Terletskaya EN, Timofeev AV, Elbert LB, Lashkevich VA, Drozdov SG. Use of protamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines. *Vaccine* 1991 Mar;9(3):207-9. PMID 1645900.
354. Thyagarajan B, McCormick-Graham M, Romero DP, Campbell C. Characterization of homologous DNA recombination activity in normal and immortal mammalian cells. *Nucleic Acids Res* 1996 Oct 15;24(20):4084-91. PMID 8918816 (full text article available free at this link).
355. Ruscetti SK. Generation of mink cell focus-inducing retroviruses: a model for understanding how viral-viral and viral-cellular interactions can result in biological consequences. *Dev Biol (Basel)* 2001;106:163-7; discussion 167-8, 253-63. PMID 11761228.
356. Hilleman MR. History, precedent, and progress in the development of mammalian cell culture systems for preparing vaccines: safety considerations revisited. *J Med Virol* 1990 May;31(1):5-12. PMID 2198327.
357. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. *J Natl Cancer Inst* 1999 Jan 20;91(2):119-34. PMID 9923853.
358. Arrington AS, Lednicky JA, Butel JS. Molecular characterization of SV40 DNA in multiple samples from a human mesothelioma. *Anticancer Res* 2000 Mar-Apr;20(2A):879-84. PMID 10810370.
359. Vilchez RA, Madden CR, Kozinetz CA, Halvorson SJ, White ZS, Jorgensen JL, Finch CJ, Butel JS. Association between simian virus 40 and non-Hodgkin lymphoma. *Lancet* 2002 Mar 9;359(9309):817-23. PMID 11897278.
360. Shivapurkar N, Harada K, Reddy J, Scheuermann RH, Xu Y, McKenna RW, Milchgrub S, Kroft SH, Feng Z, Gazdar AF. Presence of simian virus 40 DNA sequences in human lymphomas. *Lancet* 2002 Mar 9;359(9309):851-2. PMID 11897287.
361. Bu X, Zhang X, Zhang X, et Al. A study of simian virus 40 infection and its origin in human brain tumors. *Zhonghua Liu Xing Bing Xue Za Zhi* 2000 Feb;21(1):19-21. PMID 11860751.
362. Butel JS, Jafar S, Wong C, Arrington AS, Opekun AR, Finegold MJ, Adam E. Evidence of SV40 infections in hospitalized children. *Hum Pathol* 1999 Dec;30(12):1496-502. PMID 10667429.
363. von Mettenheim AE. Studies on simian viruses as possible contaminants of inactivated virus vaccines. I. Direct and serologic detection of simian adenovirus SV20. *Zentralbl Bakteriol [Orig A]* 1975 Jul;232(2-3):131-40. PMID 1179876.

364. Schuurman R, van Steenis B, Sol C. Bovine polyomavirus, a frequent contaminant of calf serum. *Biologicals* 1991 Oct;19(4):265-70. PMID 1665699.
365. Nettleton PF, Rweyemamu MM. The association of calf serum with the contamination of BHK21 clone 13 suspension cells by a parvovirus serologically related to the minute virus of mice (MVM). *Arch Virol* 1980;64(4):359-74. PMID 7396725.
366. Fong CK, Gross PA, Hsiung GD, Swack NS. Use of electron microscopy for detection of viral and other microbial contaminants in bovine sera. *J Clin Microbiol* 1975 Feb;1(2):219-24. PMID 51855.
367. Erickson GA, Bolin SR, Landgraf JG. Viral contamination of fetal bovine serum used for tissue culture: risks and concerns. *Dev Biol Stand* 1991;75:173-5. PMID 1665460.
368. Kniazeff AJ, Wopschall LJ, Hopps HE, Morris CS. Detection of bovine viruses in fetal bovine serum used in cell culture. *In Vitro* 1975 Nov-Dec;11(6):400-3. PMID 172434.
369. Michalski FJ, Dietz A, Hsiung GD. Growth characteristics of bovine herpesvirus 1 (infectious bovine rhinotracheitis) in human diploid cell strain WI-38. *Proc Soc Exp Biol Med* 1976 Feb;151(2):407-10. PMID 175382.
370. Egyed L. Bovine herpesvirus type 4: a special herpesvirus (review article). *Acta Vet Hung* 2000;48(4):501-13. PMID 11402667.
371. Egyed L. Replication of bovine herpesvirus type 4 in human cells in vitro. *J Clin Microbiol* 1998 Jul;36(7):2109-11. PMID 9650976.
372. Johnson ES. Poultry oncogenic retroviruses and humans. *Cancer Detect Prev* 1994;18(1):9-30. PMID 8162609.
373. For example, see Nevins JR, "Cell Transformation by Viruses", in Knipe DM et al (ed.), 2001. *Fields Virology* (4th ed), Vol. I, chapter 10, p.245-283. Lippincott.
374. Joklik WK, "Tumor Viruses", in Joklik WK et al, 1992. *Zinsser Microbiology* (20th ed), chapter 59, p.869-905. Appleton & Lange.
375. Felder MP, Eychene A, Laugier D, Marx M, Dezelee P, Calothy G. Steps and mechanisms of oncogene transduction by retroviruses. *Folia Biol (Praha)* 1994;40(5):225-35. PMID 7895853.
376. Harris RJ, Dougherty RM, Biggs PM, Payne LN, Goffe AP, Churchill AE, Mortimer R. Contaminant viruses in two live virus vaccines produced in chick cells. *J Hyg (Lond)* 1966 Mar;64(1):1-7. PMID 4286627.
377. Payne LN, Biggs PM, Chubb RC, Bowden RS. Contamination of egg-adapted canine distemper vaccine by avian leukosis virus. *Vet Rec* 1966 Jan 8;78(2):45-8. PMID 4285488.
378. Knipe DM et al (ed.) 2001. *Fields Virology* (4th ed), Vol. I, p.1103. Lippincott.
379. Johnson JA, Heneine W. Characterization of endogenous avian leukosis viruses in chicken embryonic fibroblast substrates used in production of measles and mumps vaccines. *J Virol* 2001 Apr;75(8):3605-12. PMID 11264350.
380. Maudru T, Peden KW. Analysis of a coded panel of licensed vaccines by polymerase chain reaction-based reverse transcriptase assays: a collaborative study. *J Clin Virol* 1998 Jul 24;11(1):19-28. PMID 9784140.
381. Tsang SX, Switzer WM, Shanmugam V, Johnson JA, Goldsmith C, Wright A, Fadly A, Thea D, Jaffe H, Folks TM, Heneine W. Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps vaccines derived from chicken cells: investigation of transmission to vaccine recipients. *J Virol* 1999 Jul;73(7):5843-51. PMID 10364336.
382. Hussain AI, Shanmugam V, Switzer WM, Tsang SX, Fadly A, Thea D, Helfand R, Bellini WJ, Folks TM, Heneine W. Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients. *Emerg Infect Dis* 2001 Jan-Feb;7(1):66-72. PMID 11266296. Full article text available at www.cdc.gov/ncidod/eid/vol7no1/hussain.htm
383. Arshad SS, Howes K, Barron GS, Smith LM, Russell PH, Payne LN. Tissue tropism of the HPRS-103 strain of J subgroup avian leukosis virus and of a derivative acutely transforming virus. *Vet Pathol* 1997 Mar;34(2):127-37. PMID 9066079.

384. Johnson ES, Overby L, Philpot R. Detection of antibodies to avian leukosis/sarcoma viruses and reticuloendotheliosis viruses in humans by western blot assay. *Cancer Detect Prev* 1995;19(6):472-86. PMID 8925516.
385. Raines MA, Maihle NJ, Moscovici C, Crittenden L, Kung HJ. Mechanism of c-erbB transduction: newly released transducing viruses retain poly(A) tracts of erbB transcripts and encode C-terminally intact erbB proteins. *J Virol* 1988 Jul;62(7):2437-43. PMID 2897475.
386. Joklik WK, "Tumor Viruses", in Joklik WK et al, 1992. *Zinsser Microbiology* (20th ed.), chapter 59, p.889. Appleton & Lange.
387. Geier MR, Stanbro H, Merrill CR. Endotoxins in commercial vaccines. *Appl Environ Microbiol* 1978 Sep;36(3):445-9. PMID 727776.
388. Kreeftenberg JG, Loggen HG, van Ramshorst JD, Beuvery EC. The limulus amebocyte lysate test micromethod and application in the control of sera and vaccines. *Dev Biol Stand* 1977;34:15-20. PMID 838139.
389. Sharma SK. Endotoxin detection and elimination in biotechnology. *Biotechnol Appl Biochem* 1986 Feb;8(1):5-22. PMID 3548752.
390. Fumarola D, Panaro A, Palma R, Mazzone A. Endotoxic contamination of biological products (ribosomal vaccines, viral vaccines and interferon). *G Bacteriol Virol Immunol* 1979 Jan-Jun;72(1-6):72-7. PMID 95449.
391. Cussler K, Godau H, Gyra H. Investigation of the endotoxin content of veterinary vaccines. *ALTEX* 1994;11(5):24-29. PMID 11178403.
392. Whitaker AM, Smith EM. Effect of bacterial toxins in serum on the chromosomes of WI-38. *Dev Biol Stand* 1976 Dec 13-15;37:185-90. PMID 801471.
393. See "What are nanobacteria?" at www.nanobaclabs.com/PageDisplay.asp?p1=6578
394. Breitschwerdt EB, Sontakke S, Cannedy A, Hancock SI, Bradley JM. Infection with *Bartonella weissii* and detection of *Nanobacterium* antigens in a North Carolina beef herd. *J Clin Microbiol* 2001 Mar;39(3):879-82. PMID 11230398. Full article text available at <http://jcm.asm.org/cgi/content/full/39/3/879?view=full&pmid=11230398>
395. Nanobacteria detected in vaccines. *NanoNews* 2001 July;1(2). Article available at <http://www.nanobaclabs.com/Files/Newsletter/JulyNANONEWS1.pdf>
396. Cell Culture Contamination Example. *Mycoplasma*. <http://www.unc.edu/depts/tcf/mycoplasma.htm>
397. Prasad E, Lim-Fong R. *Mycoplasmas*. <http://www2.provlab.ab.ca/bugs/biologos/9702mypl.htm>
398. *Mycoplasma* Detection Kit. <http://www.atcc.org/Products/MycoplasmaDetectKit.cfm>
399. Mattman LH, 2001. Cell wall deficient forms: stealth pathogens (3rd ed.). CRC Press.
400. Uphoff CC, Drexler HG. Prevention of mycoplasma contamination in leukemia -lymphoma cell lines. *Hum Cell* 2001 Sep;14(3):244-7. PMID 11774744.
401. *Mycoplasma* Detection and Elimination. <http://www.dsmz.de/mutz/mutzmyco.htm>
402. *Mycoplasma* Detection Kit. http://www.biovalley.fr/anglais/biology/mob_cc.htm
403. Kojima A, Takahashi T, Kijima M, Ogikubo Y, Tamura Y, Harasawa R. Detection of mycoplasma DNA in veterinary live virus vaccines by the polymerase chain reaction. *J Vet Med Sci* 1996 Oct;58(10):1045-8. PMID 8916012.
404. Kojima A, Takahashi T, Kijima M, Ogikubo Y, Nishimura M, Nishimura S, Harasawa R, Tamura Y. Detection of *Mycoplasma* in avian live virus vaccines by polymerase chain reaction. *Biologicals* 1997 Dec;25(4):365-71. PMID 9467032.
405. Benisheva T, Sovova V, Ivanov I, Opalchenova G. Comparison of methods used for detection of mycoplasma contamination in cell cultures, sera, and live-virus vaccines. *Folia Biol (Praha)* 1993;39(5):270-6. PMID 8206173.
406. Nicolson GL, Nass M, Nicolson N. Anthrax vaccine: controversy over safety and efficacy. *Antimicrobics and Infectious Disease Newsletter (Elsevier Science)* 2000. Article located at <http://www.flatlandbooks.com/anthrax.html>

407. Thornton DH. A survey of mycoplasma detection in veterinary vaccines. *Vaccine* 1986 Dec;4(4):237-40. PMID 3799018.
408. Kong F, James G, Gordon S, Zelynski A, Gilbert GL. Species-specific PCR for identification of common contaminant mollicutes in cell culture. *Appl Environ Microbiol* 2001 Jul;67(7):3195-200. PMID 11425741.
409. Mycoplasma testing by PCR. <http://locus.umdj.edu/nia/qc/myco.html>
410. Mycoplasma sp. Reagent Set. http://www.euroclone.net/mol_biology/mycoplasma.htm
411. Macomber PB. Cancer and cell wall deficient bacteria. *Med Hypotheses* 1990 May;32(1):1-9. PMID 2190063.
412. Baseman JB, Tully JG. Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. *Emerg Infect Dis* 1997 Jan-Mar;3(1):21-32. PMID 9126441. Full text article available at <http://www.cdc.gov/ncidod/eid/vol3no1/baseman.htm>
413. Gartler SM. Apparent HeLa cell contamination of human heteroploid cell lines. *Nature* 1968 Feb 24;217(5130):750-1. PMID 5641128.
414. Lavappa KS. Survey of ATCC stocks of human cell lines for HeLa contamination. *In Vitro* 1978 May;14(5):469-75. PMID 566722.
415. Nelson-Rees WA, Daniels DW, Flandermeyer RR. Cross-contamination of cells in culture. *Science* 1981 Apr 24;212(4493):446-52. PMID 6451928.
416. Gold M. The cells that would not die. *Science* 81 1981 April; 29-35.
417. Gold M, 1986. *A Conspiracy of Cells: One Woman's Immortal Legacy and the Medical Scandal It Caused*. State University of New York Press.
418. Demidova SA, Tsareva AA, Mikhailova GR, Perekrest VV, Gushchin BV. Several methodologic problems in the control of cell cultures. *Vopr Virusol* 1976 May-Jun;(3):371-9. PMID 983006.
419. Hukku B, Halton DM, Mally M, Peterson WD Jr. Cell characterization by use of multiple genetic markers. *Adv Exp Med Biol* 1984;172:13-31. PMID 6328905.
420. MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies crosscontamination of human tumor cell lines arising at source. *Int J Cancer* 1999 Nov 12;83(4):555-63. PMID 10508494.
421. Stacey GN. Cell contamination leads to inaccurate data: we must take action now. *Nature* 2000 Jan 27;403(6768):356. PMID 10667765.
422. Kniss DA, Xie Y, Li Y, Kumar S, Linton EA, Cohen P, Fan-Havard P, Redman CW, Sargent IL. ED(27) Trophoblast-like Cells Isolated from First-trimester Chorionic Villi are Genetically Identical to HeLa Cells Yet Exhibit a Distinct Phenotype. *Placenta* 2002 Jan;23(1):32-43. PMID 11869090.
423. Buttner M, Oehmig A, Weiland F, Rziha HJ, Pfaff E. Detection of virus or virus specific nucleic acid in foodstuff or bioproducts--hazards and risk assessment. *Arch Virol Suppl* 1997;13:57-66. PMID 9413526.
424. Monath TP, Cropp CB, Harrison AK. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. *Lab Invest* 1983 Apr;48(4):399-410. PMID 6300550.
425. Burke DS, Monath TP, "Flaviviruses", in Knipe DM et al (ed.), 2001. *Fields Virology* (4th ed), Vol. I, chapter 33, p.1057. Lippincott. Hoffman PN, Abuknesha RA, Andrews NJ, Samuel D, Lloyd JS. A model to assess the infection potential of jet injectors used in mass immunisation. *Vaccine* 2001 Jul 16;19(28-29):4020-7. PMID 11427278.
426. Canter J, Mackey K, Good LS, Roberto RR, Chin J, Bond WW, Alter MJ, Horan JM. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. *Arch Intern Med* 1990 Sep;150(9):1923-7. PMID 2393323.
427. Brink PR, van Loon AM, Trommelen JC, Gribnau FW, Smale-Novakova IR. Virus transmission by subcutaneous jet injection. *J Med Microbiol* 1985 Dec;20(3):393-7. PMID 4068027.
428. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR.

- Human hepatitis B vaccine from recombinant yeast. *Nature* 1984 Jan 12-18;307(5947):178-80. PMID 6318124.
429. Hilleman MR. Yeast recombinant hepatitis B vaccine. *Infection* 1987 Jan-Feb;15(1):3-7. PMID 2437037
430. Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccine Research and Review, December 1996. Full article available at <http://www.fda.gov/cber/gdlns/plasmid.txt>
431. Ho M, Ryan A, Cummins J, Traavik T. Slipping through the regulatory net: 'Naked' and 'free' nucleic acids. TWN Biotechnology and Biosafety Series No. 5, 2001. Available at <http://www.twinside.org.sg/title/biod5.htm>
432. Petricciani JC. Safety issues relating to the use of mammalian cells as hosts. *Dev Biol Stand* 1985;59:149-53. PMID 3891461.
433. Phillips A. Dispelling vaccination myths: an internationally published, referenced report. 1998. Report available at <http://www.unc.edu/~aphillip/www/chf/myths/dvm1.htm>
434. For statistics regarding adverse events, see the link at <http://www.unc.edu/~aphillip/www/chf/myths/dvm11.htm>
435. See a discussion of issues surrounding proposed forced smallpox vaccination at: Fisher, BL. Smallpox and forced vaccination: what every American needs to know. *The Vaccine Reaction*, Winter 2002. Article available at <http://www.909shot.com/smallpoxspecialrpt.htm>. The entire text of the Model State Emergency Health Powers Act, currently being considered by the various U.S. state governments is available at <http://www.publichealthlaw.net/MSEHPA/MSEHPA2.pdf>
436. National Vaccine Program Office, Vaccine Fact Sheets: Vaccine Product Approval Process. Article available at http://www.cdc.gov/od/nvpo/fs_table11_doc2.htm
437. Garnick RL. Raw materials as a source of contamination in large-scale cell culture. *Dev Biol Stand* 1998;93:21-9. PMID 9737373.
438. Fadly AM, Smith EJ. Isolation and some characteristics of a subgroup J-like avian leukosis virus associated with myeloid leukemia in meat-type chickens in the United States. *Avian Dis* 1999 Jul-Sep;43(3):391-400. PMID 10494407.
439. Grunder AA, Benkel BF, Chambers JR, Sabour MP, Gavora JS, Dickie JW. Characterization of four endogenous viral genes in semi-congenic lines of meat chickens. *Poult Sci* 1999 Jun;78(6):873-7. PMID 10438132.
440. Pham TD, Spencer JL, Johnson ES. Detection of avian leukosis virus in albumen of chicken eggs using reverse transcription polymerase chain reaction. *J Virol Methods* 1999 Mar;78(1-2):1-11. PMID 10204692.
441. Kopelovich L. Are all normal diploid human cell strains alike? Relevance to carcinogenic mechanisms in vitro. *Exp Cell Biol* 1982;50(5):266-70. PMID 7141068.
442. A Finnish study also showed the presence of nanobacteria in bovine serum used in vaccines. (*Mol. Biol. Cell, Suppl.*, Vol. 7, (1996): 517a, Fatal (fetal) bovine serum: discovery of Nanobacteria SUBACUTE SCLEROSING PANENCEPHALITIS AND SALK VACCINE *The Lancet*, Volume 302, Issue 7832, Pages 763-765 <http://www.virology.ws/2010/04/13/poliovirus-vaccine-sv40-and-human-cancer/> :
443. Garcea, R., & Imperiale, M. (2003). Simian Virus 40 Infection of Humans *Journal of Virology*, 77 (9), 5039-5045 DOI: 10.1128/JVI.77.9.5039-5045.2003
444. López-Ríos F, Illei PB, Rusch V, & Ladanyi M (2004). Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. *Lancet*, 364 (9440), 1157-66 PMID: 15451223
445. PEDEN, K. (2008). Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s *Virology*, 370 (1), 63-76 DOI: 10.1016/j.virol.2007.06.045
446. *Occupational Medicine* 2007 57(8):564-568; doi:10.1093/occmed/kqm079

447. **Simian virus 40 and mesothelioma in Great Britain**
<http://occm.oxfordjournals.org/cgi/content/full/57/8/564> :
<http://www.uow.edu.au/~bmartin/dissent/documents/AIDS/Elswood94.html>
448. *Human exposure to SV40. Am J Epidemiol.* 1976 Jan;103(1):1-12. *Human exposure to SV40: Shah K, Nathanson N.*
449. Adventitious pestivirus RNA in live virus vaccines against bovine and swine diseases, *Vaccine*, Volume 13, Number 1, January 1995 , pp. 100-103(4) Another study - Evidence of Pestivirus RNA in Human Virus Vaccines, *JOURNAL OF CLINICAL MICROBIOLOGY*, June 1994, p. 1604-1605 <http://jcm.asm.org/cgi/reprint/32/6/1604.pdf>
450. National Vaccine Information Center (NVIC). **Rotarix and Rotarix Vaccine.**
<http://www.nvic.org/Vaccines-and-Diseases/Rotavirus.aspx>
451. **FDA.** News Release: Components of Extraneous Virus Detected in Rotarix Vaccine: *No Known Safety Risk, FDA Recommends Clinicians Temporarily Suspend Use of Vaccine As Agency Learns More.* March 22, 2010.
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm205625.htm>
452. **Racaniello V.** Deep sequencing reveals viral vaccine contaminants. *www.virology.ws.* March 29, 2010. http://www.virology.ws/2010/03/29/DEEP-SEQUENCING-REVEALS-VIRAL-VACCINE-CONTAMINANTS/?UTM_SOURCE=FEEDBURNER&UTM_MEDIUM=EMAIL&UTM_CAMPAIGN=FEED%253A+VIRLOGYBLOG+%2528VIROLOGY
453. **FDA.** Detection of DNA from PCV1 in Rotarix. March 22, 2010.
<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm205545.htm>
454. **FDA.** Memorandum: Review of Vero Cell Banks used for Vaccine Production and Adventitious Agent Testing of Virus Seeds and Vaccine Human Rotavirus Vaccine (HRV) – Rotarix. April 1, 2008.
<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134138.htm>
455. **FDA.** Summary Basis for FDA Regulatory Action – Rotarix. June 4, 2007.
<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133543.htm>
456. **European Medicines Control Agency.** Evaluation of Medicines for Human Use: Rotarix Vaccine (*Control of Materials (Reagents)* page 4). 2006.
<http://www.ema.europa.eu/humandocs/PDFs/EPAR/rotarix/063906en6.pdf>
457. **European Medicines Control Agency.** Evaluation of Medicines for Human Use: RotaTeq Vaccine (*Active Substance (Manufacture)*). Pages 3-10.
<http://www.ema.europa.eu/humandocs/PDFs/EPAR/Rotateq/066906en6.pdf>
458. **FDA.** Memorandum: Clinical Review of New Biologics License Application – RotaTeq (*Description of the Product*). Page 12. April 6, 2005.
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142304.pdf>
459. **FDA.** Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. February 2010.
<http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf>
460. Bookchin D, Schumacher J. **The Virus and the Vaccine: The True Story of a Cancer-Causing Monkey Virus, Contaminated Polio Vaccine, and the Millions of Americans Exposed.** St. Martin's Press: New York. 2004. <http://www.nvic.org/resource-center/books.aspx>
461. Fisher BL. Congressional Testimony: The SV-40 Virus: Has Tainted Polio Vaccine Caused an Increase in Cancer? U.S. House Government Reform Committee. September 10, 2003.
<http://www.nvic.org/vaccines-and-diseases/Polio-SV40/BLFTestimonySV40.aspx>
462. U.S. Congress. Congressional Hearing: Preventing Another SV40 Tragedy: Are Today's Vaccine Safety Protocols Effective? U.S. House Government Reform Committee. November 13, 2003. http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=108_house_hearings&docid=f:92772.wais
463. Carlsen W. Rogue Virus in the Vaccine: Early Polio Vaccine Harbored Virus Now Feared to Cause Cancer in Humans. *San Francisco Chronicle.* July 15, 2001.

- <http://www.sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/2001/07/15/MN193825.DTL>
464. Carlsen W. Quest for the Origin of AIDS: Controversial Book Spurs Search for How the Worldwide Scourge of HIV Began. San Francisco Chronicle. January 14, 2001.
<http://www.sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/2001/01/14/MN140641.DTL>
465. FDA. Designer Cells as Substrates for the Manufacture of Viral Vaccines. 2001.
http://www.fda.gov/OHRMS/DOCKETS/AC/01/briefing/3750b1_01.pdf
466. WHO. Initiative for Vaccine Research: Use of Cell Lines for the Production of Influenza Virus Vaccines: the Appraisal of Technical, Manufacturing and Regulatory Considerations. April 10, 2007.
http://www.who.int/vaccine_research/diseases/influenza/WHO_Flu_Cell_Substrate_Version3.pdf
467. FDA. Vaccines & Related Biological Products Advisory Committee. Safety & Effectiveness of Purified Recombinant Influenza Hemagglutinin Vaccine for the Prevention of Influenza (FluBlok). November 19, 2009.
<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM197912.pdf>
468. FDA. Background on Rotavirus Vaccines: How Many Doses of Rotarix Have Been Sold? March 22, 2010.
<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm205543.htm>
469. Schultz R, Everything You Need To Know About Vaccines. Seminar Danbury, CT, June 15, 2007. Sponsored by Cavaliers of the Northeast.
470. Ford R DVM MS Diplomate ACVIM, Vaccines and Vaccination Building the Protocol-Implementing the Guidelines. Framingham, MA July 25, 2007. Sponsored by Merial.
471. CDC Leptospirosis Information Sheet
<http://www.cdc.gov/ncidod/dbmd/diseaseinfo/Leptospirosis>
472. Hershey-Grove D MPH, Commonwealth of Massachusetts, executive Office of the Health and Human Resources, Department of Public Health, bureau of Communicable Disease Control, Office of Integrated Surveillance and Informatics, William A. Hinton State Laboratory Institution, 305 South Street, Jamaica Plain, MA 02130.
473. Aker N, James ED, Johnston AM et al, Leptospirosis in pregnancy: an unusual and relatively unrecognized cause of intrauterine death in man. Journal of Obstetrics and Gynecology 1996 May, 16; (3):163-165.
474. Kasasira R and Bagala A, UPDF soldiers poisoned in Somalia. Kampala
http://www.monitor.co.ug/artman/publish/news/UPDF_soldiers_poisoned_in_Somalia_88893.shtml.
475. Vashi NA, Reddy P, Wayne DB, Sabin B, Bat-associated Leptospirosis. J Gen Intern Med. PMID: 200112224 PubMed [Epub ahead of print].
476. Stock D, Children's Pool, LaJolla, California Nov 8, 2009:1-2
477. Masuzawa T, Leptospirosis in squirrels imported from the United States to Japan. US National Center for Infectious Diseases 2006.
478. Campa C, Varela LE, Gilling E et al., Homeoprophylaxis Homeopathic Immunization and Nosodes against epidemics: Cuban experience in Nosodes 2008 International Meeting Proceedings Havana, Cuba 10-12 Dec 2008.
<http://www.finlay.sld.cu/nosodes/en/ProgramaNosodes2008.pdf>
479. McClain JBL, Ballon WR, Harrison SM, Doxycycline therapy for Leptospirosis. Ann Intern Med 1984 100:696-698.
480. Takafuji ET, Kirkpatrick JW, Miller RN et al., An efficacy trial of Doxycycline chemoprophylaxis against Leptospirosis. NEJM. Feb 23 1984; 310 (8):497-500.
481. Levett PN and Haake D, Leptospira: Species (Leptospirosis) Elsevier
<http://www.elsevierjapan.com> page 5.
482. Smythe LD, Smith IL, Smith GA et al., A quantifiable PCR (Taqma) assay for pathogenic Leptospira spp. 2 BMC Infect Dis 2002 July 8;2(1):13.
483. Koizumi N, Watanabe H, Leptospirosis vaccines: Past, Present and Future. J Postgrad Med 2005; 51:210-4 (page 210).

484. Goldstein RE, Leptospirosis Epidemiology Pathogenesis and Zoonotic Impact on Veterinary Practitioner. Insights in Veterinary Medicine 2007 Aug; 5(2):3.
485. Goldstein RE, Leptospirosis Epidemiology Pathogenesis and Zoonotic Impact on Veterinary Practitioner Insights in Veterinary Medicine 2007 Aug; 5(2):5.
486. Goldstein RE, Lin RC, Lanstron CE et al., Influences of infecting serogroup on clinical features of Leptospirosis in dogs. J Vet Intern Med.2006; 20(3):489-494
487. Levett PN, Usefulness of serologic analysis as a predictor of the infecting serovar in patients with severe Leptospirosis. Clin Infect Disease 2003;36; 447-452.
488. Bajani MD, Asford DA, Bragg SI, et al., Evaluation of four commercially available rapid screening tests for diagnosis of Leptospirosis. J Clin Microb. 2003; 41:803-809.
489. Oregon State University of Veterinary Diagnostic Laboratory Leptospirosis Real Time PCR DNA for acute onset of illness <http://oregonstate.edu/vetmed/vdl/vdl.htm>
490. IDEXX Introduces Real PCR TCM Test for canine Leptospirosis <http://www.idexx.com/pcr>
491. Goldstein R, Canine Leptospirosis. Department of Clinical Sciences, College of Veterinary Medicine Cornell University, Ithaca, New York. Email rg225@cornell.edu
492. Goldstein RE Leptospirosis Epidemiology and Pathogenesis and Zoonotic Impact on Veterinary Practitioners. Insights in Veterinary Medicine Aug 2007:5 (2):4.
493. Schultz R, What Every Veterinarian Needs to Know About Canine and Feline Vaccines and Vaccination Programs with an emphasis on recombinant Vaccines, Warwick, RI April 16, 2008 Sponsored by Merial.
494. Goldstein R, Canine Leptospirosis epidemiology and Pathogenesis and Zoonotic Impact on Veterinary Practitioners. Insights in Veterinary Medicine Aug 2007:5(2):4.
495. Takafuji ET, Kirkpatrick JW, Miller RN et al., An efficacy trial of Doxycycline chemoprophylaxis against Leptospirosis NEJM Feb 23 1984:310(8):497-500.
496. Levett PN Leptospirosis. Clin Microbial Rev 2001; 14:296-326.
497. Feigin RD, Lobes LA, Anderson DM, et al., Human Leptospirosis from vaccinated dogs. Am Intern Med 1973;79:777-785.
498. Berkelman RN, Human Illness Associated with the use of veterinary vaccines. Emerging Infections CID 2003 (1 August); 37:407-414.
499. Meites E, Jay MT, Deresinski S, et al., Reemerging Leptospirosis, California. Emerging Infectious Diseases March 2004; 10(3):406-411. <http://www.cdc.gov/eid>
500. Srivastava SK, Prospects of developing Leptospira vaccines for animal. Indian Journal of Medical Microbiology. 2006; 24(4):331-336.
501. Klassen HL, Molkenboer MJ, Vrijenhoek MP, Kaashoek MJ, Duration of immunity in dogs vaccinated against Leptospirosis with a bivalent inactivated vaccine. Vet Microbiol 2003 Aug 29; 95 (1-2):121-132.
502. Wohl JS, Canine Leptospirosis in the Compendium Nov 1996; 18 (11):1215-41.
503. Fauks WF, Dog owner worries about Leptospirosis vaccine reaction. The Edmond Sun http://www.edmondsun.com/features/local_story_285200506.html
504. Bali Dogs, Leptospirosis no longer recommended for household urban dogs <http://kertabesung.blogspot.com/2009/02/leptospirosis-in-dogs.html#links>
505. Reidsville Veterinary Hospital partnering with Pfizer http://www2.godanriver.com/gdr/news/local/rockingham_news/article/leptospirosis
506. HogenEsch H, Azcona-Olievera J, Scott-Moncreiff C, et al., Vaccine-induced Autoimmunity in the Dog. Adv Vet med 1999; 41:733-744.
507. Kuo P, Kowal C, Tadmor B, et al., Microbial Antigens can elicit autoantibody production a potential pathway to autoimmune disease in Annals of the NY Academy of Science 1997;815 (B):230-236.
508. Olsen NJ, Chen PP, Immunogenetics of auto antibodies and autoimmune disease.

Current Opinion in Rheumatology 1991 Jun; 3(3):391-7.

509. Oldstone MBA, Relationship between major histocompatibility antigens and disease. Bull World Health Organ, 1975; 52:479-486.
510. Latov N, Wu A, Chin R et al., Neuropathy and cognitive impairment following vaccination with the Osp A protein of Borrelia burgdorferi. Journal Peripheral Nerve Society, Inc., 2004; 9 (3):165-167.
511. Otto A, Lyme Vaccine Linked to Autoimmune Arthritis. Pharmacy Today January 2001;7(1):10
512. Rathinam SR. Ocular Leptospirosis. Curr Opin Ophthalmol 2002; 13:381-6.
513. DeCava J, Vaccination Examining the Record. Selene River Press, Fort Collins, CO 2005 page 30.
514. Moore GE, Guphill LF, Ward MD et al., Adverse events within 72 hours of vaccination. JAVMA 2005 Oct 1; 227 (7):1102-8.
515. AO batulkachi RC, Daher EF, Camargo ED et al., Leptospirosis severity may be associated with intensity of humoral immune response. Rev Int Med Trop Sao Paulo 2002; 44:79-83.
516. WHO Memoranda Virus associated immunopathology; animal models and implications for human disease2. Cell mediated immunity autoimmune disease genetics and implications for clinical research. 1972;47 (2)
517. Person DA, Leptospirosis in the Pacific; Tripler Army Medical Center. Medical Surveillance Monthly Report; 4:12-14.
518. Goldstein R, Canine Leptospirosis epidemiology and Pathogenesis and Zoonotic Impact on Veterinary Practitioners. Insights in Veterinary Medicine Aug 2007:5(2):4.
519. Goldstein R, Canine Leptospirosis epidemiology and Pathogenesis and Zoonotic Impact on Veterinary Practitioners. Insights in Veterinary Medicine Aug 2007:5(2):4.
520. Klassen HL, Molkenboer MJ, Vrijenhoek MP, Kaashoek MJ, Duration of immunity in dogs vaccinated against Leptospirosis with a bivalent inactivated vaccine. Vet Microbiol 2003 Aug 29; 95 (1-2):121-132.
521. Cohen Hsiu-Yi, A Shot in the Dark. Dogs Today Nov 2008:15-19
www.dosgtodaymagazine.co.uk
522. Girard M, WHO recommendations scientific flaws or criminal misconduct. Journal of American Physicians and Surgeons 2005; 11:22-23.
523. Wodarg W, Faked pandemics, a threat to health. PACE Plenary session social affairs Council of Europe to investigate WHO Jan 25-29, 2010.
524. O'Driscoll C, Complaint letter against Intervet Ltd's National Vaccination Month to Advertising Standards Authority in London, UK. 4 Mar 2008.
525. Fort Dodge Dear Doctor News updates and practice tips for today's veterinarians Oct/Nov. 2004; 1(3).
526. WHO IARC International Agency for Research on Cancer; Summaries and evaluations surgical implants and other foreign bodies 1999 Feb 23; 74:24305-310.
527. Ramanujan K, Study; new vaccine delivery system may be more effective .Provided by Cornell University <http://www.physorg.com/news183663284.html>
528. Intervet Ltd-National Vaccination Month Campaign
529. <http://www.future-of-vaccination.co.uk/kennel-cough-vaccination.asp>
530. *Human Illness Associated with Use of Veterinary Vaccines*, Ruth L. Berkelman, CID 2003:37 (1 August)
531. *Bone*. 1991;12(3):195-201. *Canine distemper virus localised in bone cells of patients with Paget's disease.*